THE BIBLE

of

HEALTH, LONGEVITY, AND MUSCLE

Edition 1

Contents

PART I — THE BIOLOGY & MEDICINE OF LONGEVITY

Chapter 1 — The Hallmarks of Aging

Chapter 2 — The Big Levers of Lifespan & Healthspan

Chapter 3 — Longevity Pharmacology & Medical Interventions

PART II — TRAINING SCIENCE

Chapter 4 — Mechanisms of Hypertrophy & Strength

Chapter 5 — Hypertrophy Programming: Volume Landmarks (MV / MEV / MAV / MRV)

Chapter 6 — Intensity, Load & Training to Failure

Chapter 7 — Exercise Selection, Technique & Range of Motion

Chapter 8 — Strength, Power & Periodization

Chapter 9 — Cardiovascular & Metabolic Conditioning (incl. HIIT & calorie burn)

Chapter 10 — Recovery, Soreness, Sleep & Overtraining

PART III — NUTRITION & BODY COMPOSITION

Chapter 11 — Energy Balance, Weight Loss & Fat Loss (incl. TDEE, FFMI & lean mass)

Chapter 12 — Protein & Macronutrients for Muscle

Chapter 13 — Diet Frameworks (and the carnivore question)

Chapter 14 — Insulin: How the Master Storage Hormone Works, and How It Breaks

Chapter 15 — The Mitochondria: The Cellular Powerhouse, and How CoQ10, NAD^+, NMN & NR Fit In

PART IV — ORGAN-SYSTEM HEALTH

Chapter 16 — Cardiovascular Health

Chapter 17 — Bone & Musculoskeletal Health

Chapter 18 — Brain & Mental Health

Chapter 19 — Liver Health

Chapter 20 — Kidney & Excretory Health

Chapter 21 — Respiratory Health

Chapter 22 — Gastrointestinal Health

Chapter 23 — Reproductive & Hormonal Health (incl. clinical HRT/TRT)

Chapter 24 — Skin, Hair & Dermatological Anti-Aging

PART V — SUPPLEMENTS (EVIDENCE-GRADED)

Chapter 25 — How to Read Supplement Evidence

Chapter 26 — Foundational Tier

Chapter 27 — Performance Tier

Chapter 28 — Longevity & Metabolic Tier

Chapter 29 — Recovery, Energy, Brain & Sleep

Chapter 30 — Fat Burners & "Shred" Stacks

Chapter 31 — IV Therapies & Injectable Wellness

Chapter 32 — NAD^+, NMN, NR, Multivitamins & Micronutrients

Chapter 33 — Supplement Dosing Reference Tables

PART VI — PERFORMANCE PHARMACOLOGY (clinical / educational)

Chapter 34 — Hormone Therapy: TRT & HRT Pharmacology

Chapter 35 — Anabolic-Androgenic Steroids: Pharmacology & Harm Profile

Chapter 36 — Ancillaries: Aromatase Inhibitors & SERMs

Chapter 37 — Frontier Compounds: Myostatin Inhibitors, SARMs, Peptides & Gene Therapy

Chapter 38 — Non-Steroidal Ergogenics: Clenbuterol & Others

PART VII — SYNTHESIS & APPENDICES

Chapter 39 — Putting It Together

APPENDICES

REFERENCES & FURTHER READING

PART I — THE BIOLOGY & MEDICINE OF LONGEVITY

Chapter 1 — The Hallmarks of Aging

▣ Active Summary

The core idea. Aging is not a single clock ticking down. It is the gradual accumulation of damage and the failure of the body's repair and maintenance systems, expressed through a defined set of interacting cellular mechanisms. The dominant scientific framework is the **"Hallmarks of Aging"** (López-Otín[1] et al., *Cell* 2013; expanded in 2023 to **twelve hallmarks**[2]). Each hallmark (1) appears with age, (2) accelerates aging when experimentally worsened, and (3) slows aging when targeted.

The twelve hallmarks, in three functional groups: - **Primary (the causes of damage):** genomic instability · telomere attrition · epigenetic alterations · loss of proteostasis · disabled macroautophagy. - **Antagonistic (protective responses that turn harmful in excess or with time):** deregulated nutrient sensing · mitochondrial dysfunction · cellular senescence. - **Integrative (the consequences that produce the aging phenotype):** stem-cell exhaustion · altered intercellular communication · chronic inflammation ("inflammaging") · dysbiosis.


Why this matters for you. Aging is the **single largest risk factor** for almost every chronic disease — cardiovascular disease, cancer, neurodegeneration, type 2 diabetes, frailty. Slowing the *rate* of biological aging would do more for total health than curing any single disease. The hallmarks are the biological targets through which lifestyle, supplements, and medicines act.

The most actionable hallmark is **deregulated nutrient sensing** — the network of pathways (IGF-1/insulin/mTOR, AMPK, sirtuins) that reads your energy status and sets the cellular dial between *growth* and *maintenance*. This is the biological hinge on which the entire "build muscle now vs. live long" tension turns, and it is directly moved by diet, energy balance, fasting, and exercise.

The single most important practical takeaway: exercise and healthy body composition touch more hallmarks, more strongly, than any drug or supplement currently available. Everything else in this book is built on top of that foundation.

◆ Key Points

- Aging is **modifiable**, not fixed — biological age can diverge substantially from chronological age.
- There are **twelve hallmarks**, grouped into primary (damage), antagonistic (responses), and integrative (consequences).
- The hallmarks are **interconnected** — fixing or worsening one ripples through the others.
- **Nutrient sensing** is the most actionable hallmark and the key to the growth-vs-longevity trade-off.
- **Exercise is the master intervention**; pharmacology and supplements are fine-tuning on top.



The DNA double helix — genomic integrity is the first hallmark of aging.

1.1 What aging actually is — and why it is the master risk factor

We tend to think of "age" as a number of years lived. But chronological age and **biological age** — the actual functional and molecular state of your tissues — can differ by a decade or more between two people of the same birth year. One 60-year-old runs marathons with clean arteries and sharp cognition; another is frail, diabetic, and cognitively declining. The difference is the *rate at which they have aged biologically*, and that rate is partly under your control.

Biologically, **aging is the time-dependent accumulation of cellular and molecular damage, combined with the progressive failure of the systems that repair, recycle, and renew.** Early in life, damage is repaired faster than it accrues. With time the balance tips: damage outpaces repair, maintenance systems falter, and tissues lose function and resilience. The visible result is what we call aging — slower healing, lost muscle, stiffer arteries, weaker immunity, declining organ reserve.

The reason this is the central topic of any serious longevity book is a single, under-appreciated fact: **aging is the largest risk factor for almost every major chronic disease.** The risk of cardiovascular disease, most cancers, Alzheimer's, type 2 diabetes, and frailty rises *exponentially*, not linearly, with age. A 70-year-old's risk of these conditions is orders of magnitude higher than a 30-year-old's. This has a profound implication, sometimes called the **"longevity dividend"**: if you could slow the underlying *rate* of biological aging even modestly, you would simultaneously push back the onset of *all* age-related diseases at once — a far larger prize than curing any single

Chapter 2 — The Big Levers of Lifespan & Healthspan

▣ Active Summary

The core idea. Chapter 1 explained the cellular machinery of aging. This chapter answers the practical question that follows: *of everything you could possibly do, what actually moves lifespan and healthspan the most, and in what order should you spend your effort?* The honest, evidence-weighted answer is that a small number of "big levers" explain most of the modifiable variance in how long and how well you live — and an enormous amount of popular "longevity" content fixates on marginal interventions while neglecting these.

First, a distinction that reframes the whole goal. Lifespan is how long you live; **healthspan** is how long you live in good health, free of chronic disease and disability. The aim is not merely to add years to life but to add *life to years* — and ideally to **compress morbidity**, so that the period of decline at the end is as short as possible rather than a long, frail tail. The big levers improve both, but healthspan is the more honest target.

The evidence-weighted hierarchy of modifiable levers (roughly in order of impact): 1. **Don't smoke / avoid major toxins** — the single largest avoidable cause of premature death. 2. **Cardiorespiratory fitness (VO_2max)** — one of the strongest predictors of all-cause mortality known; the benefit has no observed ceiling. 3. **Muscle mass & strength** — low strength independently predicts death; resistance training adds years and defends function. 4. **Healthy body composition (low visceral fat)** — the metabolic engine behind most chronic disease. 5. **Metabolic health** — blood pressure, glucose/insulin, apoB/lipids in good ranges. 6. **Sleep** — 7–9 h; foundational to all the above. 7. **Diet quality** — whole-food, fibre-rich, adequate protein. 8. **Social connection & psychological wellbeing** — as predictive of mortality as some classic risk factors.


The compounding insight. These levers are not a menu to pick one from — they **stack multiplicatively**. Large cohort studies show that people who hit several healthy-lifestyle factors together live **~12–14 years longer** on average than those who hit none, and spend far more of that time disease-free.

The single most important practical message: train your aerobic fitness and your muscle, keep your visceral fat low, sleep well, don't smoke, eat mostly whole foods, and stay connected to people. Everything else in this book — every supplement, every drug, every optimisation — is fine-tuning on top of these Big Rocks. Get the order right and you capture ~80% of the available benefit from ~20% of the possible actions.

◆ Key Points

- The goal is **healthspan and compressed morbidity**, not just raw lifespan.
- A **handful of levers** explain most modifiable longevity; most "biohacks" are noise beside them.
- **Fitness and muscle** are the two most powerful *trainable* levers.
- **Risk markers** are not lifestyle: visceral fat, apoB, BP, and glucose are the dials disease actually runs on.
- The levers **compound** — doing several together is worth ~12–14 years.

◆



Approximate evidence-weighted ranking of the modifiable levers of healthspan. (Schematic ordering.)

2.1 Lifespan, healthspan, and the shape of the end

Imagine two people who both die at 85. The first was vigorous and independent until 83, then declined quickly over two years. The second developed type 2 diabetes at 55, had a heart attack at 62, lost mobility in their late 60s, and spent the final fifteen years in progressive disability. Same lifespan; radically different lives. The second person's experience is what we are actually trying to avoid.

This is the difference between **lifespan** (total years) and **healthspan** (years lived in good function and free of major chronic disease). For most of the twentieth century, medicine extended lifespan largely by keeping sick people alive longer — which can *lengthen* the period of morbidity. The modern longevity goal is different and better: **compression of morbidity**, a concept introduced by James Fries — pushing the onset of disease and disability as late as possible, so the frail period at the end is short and the healthy period is long. A long healthspan with a short, steep decline at the end is the realistic ideal; chasing extreme maximum lifespan while ignoring healthspan is the wrong target.

The reason the "big levers" matter is that they improve **both** lifespan and healthspan, and they do so primarily by **delaying the onset of the age-related diseases** (cardiovascular disease, type 2 diabetes, many cancers, dementia,

Chapter 3 — Longevity Pharmacology & Medical Interventions

▣ Active Summary

The core idea. This chapter covers the **drugs and medical interventions** studied for extending healthspan — the emerging field of **"geroscience" and geroprotectors** (agents that target aging itself rather than a single disease). It explains *what each agent is, how it works, how long it's typically used, and its benefits and harms* — deliberately **without personal dosing protocols**, because every one of these belongs under a clinician's supervision.


The crucial framing. There is, as of now, **no proven anti-aging drug for healthy humans.** What exists is (a) a set of **disease-treating drugs with strong evidence** that, by controlling the diseases of aging, extend healthy life (statins, antihypertensives, GLP-1 agonists, SGLT2 inhibitors), and (b) a set of **experimental geroprotectors** with compelling animal data but unproven human longevity benefit (rapamycin, metformin-for-longevity, senolytics). Do not confuse the two tiers.

The agents covered: - **Metformin** — AMPK-activating diabetes drug; longevity hypothesis under formal test (TAME); caveat: may blunt exercise adaptations. - **Rapamycin** — mTOR inhibitor; the most robust *animal* lifespan extender; immunosuppressant; experimental for humans. - **GLP-1 / GIP agonists (semaglutide, tirzepatide)** — powerful for obesity and metabolic/cardiovascular disease; watch lean-mass loss. - **Statins** — apoB/LDL-lowering; among the best-evidenced preventive drugs in medicine. - **SGLT2 inhibitors** — glucose-lowering with major heart- and kidney-protective effects. - **Senolytics** — clear "zombie" senescent cells; promising but experimental. - **Aspirin** — secondary prevention yes; routine primary prevention largely abandoned. - **HRT / TRT** — hormone restoration where clinically indicated (detailed in Ch. 23).

The honest bottom line: the lifestyle levers of Chapter 2 remain more powerful and far better evidenced than any of these drugs for a healthy person. Geroprotectors are a frontier worth understanding, not a shortcut around training, body composition, and sleep.

◆ Key Points

- **"Geroprotector"** = a drug aimed at aging itself; the field is **geroscience.**
- **Two tiers:** proven disease-drugs that extend healthy life vs **experimental** longevity drugs.
- **No drug yet beats the lifestyle levers** for a healthy person.
- All of these require **clinical supervision**; this chapter is educational, not a protocol.



How strong the human outcome evidence is for each geroprotective drug class. (Schematic.)

3.1 Treating diseases vs. treating aging — the geroscience idea

Conventional medicine treats one disease at a time: a drug for blood pressure, another for cholesterol, another for diabetes. **Geroscience** proposes something different — that because aging is the *shared upstream driver* of all these diseases (Chapter 1), a drug that slows aging itself could delay *all* of them simultaneously. An agent that does this is called a **geroprotector.**

This idea runs into a regulatory wall: "aging" is not a recognised disease indication, so a drug cannot currently be approved "to slow aging." This is precisely why the **TAME trial** (Targeting Aging with Metformin) was designed the way it is — not to test whether metformin treats any single disease, but whether it delays the *onset of multiple age-related diseases as a group*, which would establish aging itself as a treatable target and open a regulatory path for future geroprotectors. The most rigorous animal pipeline, the NIA's **Interventions Testing Program (ITP)**, tests candidate compounds for lifespan extension across multiple sites in genetically diverse mice — and a handful of agents below earned their reputation there.

The essential discipline in reading this chapter: **separate what is proven from what is promising.** Statins and antihypertensives have decades of hard-outcome RCT data. Rapamycin and senolytics have spectacular mouse data and almost no human longevity data. Both are worth understanding; they are not the same kind of evidence.

◆

3.2 Metformin

What it is. A **biguanide**, the world's most-prescribed type 2 diabetes medication, in use for decades with a strong safety record.

How it works. Metformin reduces the liver's glucose output and improves insulin sensitivity. Mechanistically it **mildly inhibits mitochondrial complex I**, which raises the AMP:ATP ratio and **activates AMPK** — the pro-maintenance, pro-longevity energy sensor from Chapter 1 — and secondarily dampens mTOR signalling. These are exactly the pathways associated with caloric restriction and longevity, which is the basis of the anti-aging hypothesis.

PART II — TRAINING SCIENCE

Chapter 4 — Mechanisms of Hypertrophy & Strength

▣ Active Summary

The core idea. Before any program makes sense, you need to understand *what actually makes a muscle grow and what makes it strong* — because hypertrophy and strength, though related, are **distinct adaptations** driven by partly different mechanisms. Get the mechanism right and every programming decision in the following chapters becomes obvious rather than arbitrary.

Hypertrophy (muscle growth) is fundamentally about **mechanical tension**. When a muscle fibre produces high force, especially while lengthened, it triggers molecular signalling (notably **mTOR**) that increases **muscle protein synthesis (MPS)**. Growth is the accumulation, over many sessions, of a **net positive balance of MPS over muscle protein breakdown (MPB)**. You do not grow during the workout; you grow during recovery from it.

The three classical "mechanisms" — mechanical tension, metabolic stress, and muscle damage — have been reranked by modern evidence: **mechanical tension is primary**; metabolic stress matters mostly *because it helps recruit more muscle fibres within a set*; and muscle **damage is a byproduct, not a goal** (excess damage just adds recovery cost). Chasing soreness and "destroying" the muscle is a mechanistic mistake.

Motor-unit recruitment and the size principle explain *why training close to failure (or with heavy loads) is necessary*: the highest-threshold motor units — the fibres with the most growth potential — are only fully recruited under high force or as fatigue forces them in near the end of a hard set. These last, effortful reps are the **"effective reps."**


Strength is partly a skill. Early strength gains are largely **neural** — better motor-unit recruitment, faster firing (rate coding), improved coordination, and reduced protective inhibition — which is why strength can rise faster than size and is highly **specific** to the trained movement. Size contributes more to strength over months and years.

Everything operates through the Stimulus–Fatigue–Recovery–Adaptation (SFRA) model and the law of **progressive overload**: impose a demand, recover from it, adapt slightly above baseline, then increase the demand. **Individual variation is large** — genetics, age, sex, and training status meaningfully change the response — and, importantly, the old idea that **transient post-workout hormone spikes drive growth has been largely debunked.**

◆ Key Points

- **Hypertrophy ≈ mechanical tension → mTOR → MPS > MPB, accumulated over time.**
- **Tension is the primary driver**; metabolic stress is secondary; damage is a byproduct, not a goal.
- **Size principle:** high-threshold (high-potential) fibres need high force *or* near-failure fatigue to recruit — these are the **effective reps.**
- **Strength = skill + size:** early gains are neural and movement-specific.
- **SFRA + progressive overload** govern all adaptation; **hormone spikes don't drive growth.**

◆



Skeletal musculature of the back — the tissue that hypertrophies with training. Gray's Anatomy (1918) — public domain.

4.1 Two related but distinct goals

People lump "getting bigger" and "getting stronger" together, but they are different adaptations that overlap rather than coincide. **Hypertrophy** is an increase in muscle size — more contractile protein, larger fibres. **Strength** is the ability to produce force in a specific task. A powerlifter and a bodybuilder are both highly trained, but the powerlifter is built for maximal force in three specific lifts (more neural, more specific), while the bodybuilder is built for maximal size across all muscles (more hypertrophy-focused, less load-specific).

They overlap because, all else equal, a bigger muscle has more force-producing potential — cross-sectional area is a major determinant of strength. But they diverge because strength is *also* a neural and skill quality that can improve substantially with little size change (and vice versa). This distinction matters because it determines how you train: **strength favours heavy, specific, lower-rep practice; hypertrophy is achievable across a wide range of loads and rep ranges as long as effort is high** (the subject of Chapters 5–6). Understanding *why* requires understanding the mechanisms below.

◆

◆

Chapter 5 — Hypertrophy Programming: Volume Landmarks (MV / MEV / MAV / MRV)

▣ Active Summary

The core idea. Of all the variables you can manipulate, **training volume — the number of hard working sets per muscle per week — is the strongest programmable driver of hypertrophy.** There is a **dose-response relationship**: within limits, more weekly sets produce more growth, with **diminishing returns** and eventually a ceiling beyond which extra volume only adds fatigue. The art of hypertrophy programming is finding *your* productive volume range and progressing within it.

The four volume landmarks (the Renaissance Periodization framework, Israetel et al.) give you a map: - **MV — Maintenance Volume:** the least that *maintains* muscle. Often ~**4–6 sets/week.** - **MEV — Minimum Effective Volume:** the least that produces *growth*. Often ~**6–10 sets/week.** - **MAV — Maximum Adaptive Volume:** the range where you grow *best* per unit of fatigue. Often ~**12–20 sets/week.** - **MRV — Maximum Recoverable Volume:** the ceiling you can recover from; beyond it you regress. Often ~**18–25+ sets/week**, highly individual.

The meta-analytic anchor: roughly **10+ hard sets per muscle per week** outperforms lower volumes (Schoenfeld[1] & Krieger), with each added set giving progressively less return. Benefits have been seen past 20 sets in some trained people, but recovery cost climbs steeply.

What counts: only **hard working sets** for the target muscle, taken within a few reps of failure (~0–4 RIR). Warm-ups and easy sets don't count; compound lifts count fully for prime movers and partially for assisting muscles.


Frequency is a tool, not separate magic: when weekly volume is equated, training a muscle **~2×/week ≈ 1×/week** for growth — but spreading volume across 2–3 sessions makes higher volumes more tolerable and each set higher quality.

How to use it: start a training block near **MEV**, **add ~1–2 sets/muscle/week** toward MAV/MRV as you adapt, and **deload** when fatigue signals you've brushed the ceiling — then restart slightly higher next block. This **"ramp then deload"** cycle is the engine of autoregulated hypertrophy.

◆ Key Points

- **Volume (hard sets/muscle/week) is the primary hypertrophy lever** — dose-response with diminishing returns.
- **Landmarks:** MV (~4–6) < MEV (~6–10) < MAV (~12–20) < MRV (~18–25+) sets/week.
- **~10+ sets/week** beats less; benefit tapers past ~20 with rising fatigue cost.
- **Count only hard sets near failure**; compounds count fully for prime movers.
- **Frequency** spreads volume; **~2×/week** per muscle is the practical sweet spot.
- **Ramp from MEV toward MRV, then deload, then restart higher.**

◆



Hypertrophy rises with weekly volume, then plateaus and declines past recoverable limits (MEV/MAV/MRV). Schematic.

5.1 Why volume is the master lever

Chapter 4 established that hypertrophy comes from accumulating **mechanical tension and effective reps**, recovering, and adapting. **Volume** is simply how you *dose* that stimulus over a week. More hard sets means more effective reps and more total tension applied to the muscle — up to the point where you can no longer recover from it. This is why, across the research, volume emerges as the variable most reliably tied to growth: when studies equate intensity and effort but vary the number of sets, the higher-volume groups generally grow more, within a recoverable range.

But "more is better" has a hard limit, because the other half of the SFRA loop is **fatigue**. Every set adds both stimulus *and* fatigue. Early sets add lots of stimulus for modest fatigue; as weekly volume climbs, each additional set adds less stimulus and more fatigue, until you reach a point where extra sets stop helping and start hurting (interfering with recovery, degrading session quality, raising injury risk). Programming is therefore a search for the **range that maximises stimulus relative to recoverable fatigue** — which is exactly what the four landmarks describe.

◆

Chapter 6 — Intensity, Load & Training to Failure

▣ Active Summary

The core idea. Volume (Chapter 5) tells you *how much*; this chapter tells you *how hard each set should be* — how heavy the load, and how close to failure to push. The two most important findings overturn a lot of gym dogma: **(1) hypertrophy is similar across a wide load range when sets are taken near failure**, and **(2) you do not need to train to absolute failure on every set** to grow.

Load and hypertrophy. Across roughly **30% to 85% of 1-rep-max (1RM)** — i.e., from ~5 reps up to ~30+ reps — **muscle growth is comparable *if* each set is taken close to failure** (Schoenfeld[2] load meta-analysis). Light and heavy loads both build muscle when effort is high. What you *cannot* do is use light weight while leaving many reps in reserve and expect growth.

Load and strength. Strength is the exception: it **favours heavy loads (~≥80% 1RM, low reps)** because strength is a specific neural skill (Chapter 4) trained best by practising heavy.


Proximity to failure is the real "intensity" for growth, measured as **Reps In Reserve (RIR)** or **RPE**. Most of the hypertrophy stimulus lives in the **last few reps before failure** (the effective reps), so training at **~0–3 RIR** captures nearly all of it.

The failure debate, resolved. With volume equated, training **to failure** vs **stopping a couple reps short** produces **similar hypertrophy** — but failure **costs more** (greater fatigue, longer recovery, and it can *blunt strength*). So the optimal default is to **stop ~1–2 RIR on most sets**, reserving true failure for low-cost, high-value contexts (the last set; isolation/machine work; lighter loads). **Avoid failure on heavy compounds.**

The catch: people chronically **overestimate** how close to failure they are — most lifters who think they have "2 in reserve" actually have 4–5. Calibrating RIR honestly is a core skill.

◆ Key Points

- **Hypertrophy is similar from ~30–85% 1RM if taken near failure** — effort matters more than load.
- **Strength favours heavy loads (~≥80% 1RM)** — it's a specific neural skill.
- **Proximity to failure (RIR/RPE) is the growth-relevant "intensity"**; **~0–3 RIR** captures most of it.
- **You don't need absolute failure every set** — it adds fatigue without much extra growth and can hurt strength.
- **Use failure on:** last sets, isolation/machines, lighter loads. **Avoid on:** heavy compounds.
- **People overestimate effort** — most "2 RIR" is really 4–5. Calibrate.



Getting close to failure matters more than hitting absolute failure every set. (Schematic.)

6.1 Two meanings of "intensity"

The word "intensity" causes confusion because it has two meanings in training:

- **Intensity of load** — how heavy the weight is, usually expressed as a **percentage of 1RM** (your one-rep maximum). 80% 1RM is "high intensity of load."
- **Intensity of effort** — how hard the set is, i.e., **how close to failure** you take it, expressed as **RIR (reps in reserve)** or **RPE (rate of perceived exertion**, where RPE 10 = failure, RPE 8 ≈ 2 RIR).

These are independent: you can take a *light* load to a *high effort* (light weight to failure) or a *heavy* load to a *low effort* (a heavy single with reps to spare). For hypertrophy, as we'll see, **intensity of effort matters more than intensity of load** within a broad range — a genuinely liberating finding. For strength, **intensity of load matters specifically.** Keeping these two senses distinct is the key to the whole chapter.

◆

6.2 Load and hypertrophy — the wide effective range

One of the most practically important findings of modern hypertrophy research: **across a broad load range — roughly 30% to 85% of 1RM — muscle growth is comparable, provided each set is taken close to failure** (Schoenfeld et al. load meta-analysis, *J Strength Cond Res* 2017). A set of ~30 reps with light weight to near-failure grows muscle much like a set of ~8 reps with heavy weight to near-failure.

The mechanism is the **size principle** from Chapter 4. With a heavy load, high force recruits the high-threshold (high-growth-potential) motor units immediately. With a light load, those units are *not* recruited at the start — but as the set continues and the lower-threshold units fatigue, the high-threshold units are progressively recruited to maintain force, until near failure they too are firing maximally. Either way, the high-potential fibres get their effective reps — **but only if the light set is taken close enough to failure.** This is the crucial caveat: **light loads only grow muscle when taken near failure**, because that's the only way fatigue forces full recruitment. Leave many reps in reserve with light weight and you simply never stimulate the fibres that matter.

The practical payoff is enormous: **you can train around injuries, joint issues, and equipment limits by changing load**, as long as you keep effort high. Sore shoulders? Train chest with lighter weight and higher reps to

◆

Chapter 7 — Exercise Selection, Technique & Range of Motion

▣ Active Summary

The core idea. Once you know your volume (Ch. 5) and intensity (Ch. 6), you have to choose *which exercises* to do and *how* to perform them. The biggest evidence shift of recent years sits here: **training a muscle while it is lengthened (stretched) is a disproportionately powerful growth stimulus** — so exercise choice and range of motion are not interchangeable details, they meaningfully change results.

Range of motion. Full range of motion generally beats partial range for hypertrophy and grows muscle more uniformly. But the *lengthened portion* of the range is where most of the growth signal lives — so much so that **partials performed only in the stretched range ("lengthened partials") match or exceed full-range training** for some muscles, while **shortened-range partials are clearly inferior.** The rule: **never skip the stretched portion of a rep.**

Resistance profile. Choose exercises where the movement is **hardest while the target muscle is long** — incline curls (biceps stretched), overhead extensions (triceps long head stretched), deep RDLs and seated leg curls (hamstrings stretched), deep squats and presses. This "stretch-loaded" profile out-grows exercises that are hardest in the shortened position.

Machines vs free weights. With effort and range matched, **hypertrophy is comparable.** Choose by stability demand, joint comfort, where the resistance loads the muscle, and how safely you can approach failure (machines win for safe failure on isolation; free weights transfer better to strength and sport). Instability training (BOSU, etc.) is **counterproductive** for size and strength.


Compound vs isolation, and order. Build around **compounds** (multi-joint, most stimulus per exercise) and add **isolation** for lagging muscles and safe failure. Train priorities **first** when fresh; "compounds before isolation" is a sensible default, not a law.

Technique, eccentrics, tempo, focus. Control the **eccentric (~1–3 s)**, lift with intent, use a **controlled-but-not-super-slow** tempo, and apply an **internal focus** (feel the muscle) for isolation and an **external focus** (move the weight) for heavy compounds.

◆ Key Points

- **Full ROM ≥ partial ROM**, and the **lengthened range** drives most growth.
- **Lengthened partials ≈ or > full ROM; shortened partials are inferior.**
- **Pick exercises hardest at long muscle lengths** (stretch-loaded resistance profile).
- **Machines ≈ free weights** for hypertrophy when matched; choose by context.
- **Compounds first, isolation to fill gaps**; control the eccentric; don't lift super-slow.

◆



Training through a full ROM — especially the lengthened position — drives more growth than short-range work. Schematic.

7.1 The principles of exercise selection

A good exercise for a given muscle satisfies several criteria, in rough priority:

1. **It loads the target muscle effectively** — ideally through a full range and especially in the stretched position (7.2–7.4).
2. **Its resistance profile challenges the muscle where the muscle is strong/long**, not just where it's already shortened.
3. **It's comfortable for your joints and lets you train hard** — pain-free, stable, and allowing progressive overload.
4. **It lets you approach failure safely** where appropriate (Ch. 6).
5. **It's logistically sustainable** — you can perform it consistently with available equipment.

Notice what's *not* on the list: "maximally activates the muscle on EMG." Surface EMG (the electrical-activation measure often cited in "best exercise" content) **does not reliably predict long-term hypertrophy** — it captures a moment of activation, not the growth stimulus across a full set and recovery. Choose exercises by the principles above, not by EMG rankings or how "hard" a movement feels in the shortened, peak-contraction position.

◆

7.2 Range of motion and the rise of stretch-mediated hypertrophy

The clearest practical advance in hypertrophy research is the elevation of the **lengthened (stretched) muscle position** to primary importance. The work of groups led by **Maeo**[1]**, Pedrosa, Wolf, Schoenfeld**[2] and others has repeatedly shown:

- **Full range of motion generally produces more, and more uniform, hypertrophy than partial range** — training through the complete movement grows the muscle along its whole length.
- The growth advantage of full ROM comes **largely from the stretched portion** of the movement. Tension at long muscle lengths — combining active force with passive tension from the stretched connective and contractile elements — is an especially potent anabolic signal.
- In striking regional studies (e.g., Maeo's comparisons of overhead vs. pushdown triceps work), loading a muscle in its **stretched position produced substantially more growth** in the relevant region — differences large enough to matter a lot over time.

Chapter 8 — Strength, Power & Periodization

▣ Active Summary

The core idea. Hypertrophy (Chapters 5–7) and **maximal strength**[1]**/power** overlap but require different emphases. Strength is a **specific neural skill** (Chapter 4), so it demands **heavy loads, low reps, long rest, and practice of the specific lifts**, organised over time through **periodization**[3] — the planned variation of training to manage fatigue and drive continued adaptation.

Periodization works. Periodised training beats non-periodised for strength. Among the validated models — **linear**, **block**, and **daily undulating (DUP)** — the differences are small; **structure and progressive overload matter more than which structure** you pick. Choose one you'll adhere to.

Training maximal strength means regularly working at **~≥80–85% 1RM** for **low reps (1–6)**, with **long rest (3–5 min)**, staying **1–3 RIR** (avoid grinding heavy compounds to failure — Ch. 6), and **practising the exact lifts** because strength transfers narrowly.


The rest-interval surprise. The old "short rest builds more muscle" idea is **wrong**. Longer rest (**≥2–3 min on compounds**) produces **more** hypertrophy *and* strength than short rest (Schoenfeld 2016), because it preserves the load and reps (volume) that drive adaptation. Use short rest only for small isolation work where systemic fatigue isn't the limiter.

Power and rate of force development are trained with **high-velocity intent**, **plyometrics**, and **contrast/complex methods** (heavy lift paired with an explosive movement to exploit post-activation potentiation).

Peaking for a strength goal uses a **taper**: sharply reduce volume (~40–60%) while keeping intensity high for 1–2 weeks, so fatigue dissipates faster than fitness and you express a peak.

◆ Key Points

- **Strength = heavy (~≥80–85% 1RM), low reps, long rest, specific practice, 1–3 RIR.**
- **Periodised > non-periodised**; linear/block/DUP are roughly comparable — adherence wins.
- **Longer rest (2–3+ min) = more strength AND hypertrophy** on compounds.
- **Power:** high-velocity intent, plyometrics, contrast/complex (post-activation potentiation).
- **Peak with a taper:** cut volume ~40–60%, keep intensity, for 1–2 weeks.



The trade-off between force and velocity — heavy strength work and explosive power work sit at opposite ends.

8.1 What maximal strength training requires

Chapter 4 established that strength is **substantially a neural skill** — recruiting and synchronising motor units, firing them fast, coordinating the movement, and reducing protective inhibition — layered on top of muscle size. Training it therefore requires conditions that develop those neural qualities and practise the specific skill:

- **High load (~≥80–85% 1RM):** near-maximal force is needed to recruit the highest-threshold units and train the nervous system to express force. This is the non-negotiable that distinguishes strength work from general hypertrophy work.
- **Low reps (~1–6):** heavy loads only allow few reps; this keeps each rep high-force and technically precise.
- **Long rest (3–5 min):** full recovery of phosphocreatine and neural drive between heavy sets, so each set is high-quality (8.4).
- **Sub-failure effort (~1–3 RIR):** grinding heavy compounds to failure is fatiguing, technically dangerous, and counterproductive (Ch. 6). Strength is built by quality heavy practice, not by failing.
- **Specificity:** you get strong at the **exact movement, load, and positions** you train. To get strong at the squat, you must squat heavy; carryover from other exercises is partial. This is why strength athletes spend real time on their competition lifts.

◆

8.2 The periodization models

Periodization is the planned, systematic variation of training variables (volume, intensity, exercise selection) over time, organised into cycles — typically **macrocycle** (the whole year/goal), **mesocycles** (blocks of ~4–8 weeks), and **microcycles** (weeks). Its purpose is to **manage fatigue, avoid plateaus and overtraining, and drive continued adaptation** by progressively overloading while strategically varying the stimulus. The main validated models:

- **Linear periodization (LP):** progress from **higher volume/lower intensity** to **lower volume/higher intensity** across a block (e.g., weeks of 4×10 → 4×6 → 4×3 → peak). Simple, predictable, excellent for novices and for peaking toward a date.

◆

Chapter 9 — Cardiovascular & Metabolic Conditioning (incl. HIIT & calorie burn)

▣ Active Summary

The core idea. Resistance training builds muscle and strength; **cardiovascular conditioning builds the oxygen-delivery and mitochondrial system that underpins endurance, recovery, metabolic health, and — above all — longevity.** As Chapter 2 established, **VO_2max[3] (maximal oxygen uptake) is one of the strongest predictors of all-cause mortality known**, with no observed ceiling of benefit (Mandsager[3] et al., *JAMA Netw Open* 2018). Conditioning is not optional for a long, healthy life.

Two engines. Build cardio with a **two-tier approach**: a **base of easy aerobic ("Zone 2") work** to build mitochondria, capillaries, and fat-oxidation capacity; plus a **smaller dose of high-intensity intervals** to raise the VO_2max ceiling. The best-validated interval protocol is the **Norwegian 4×4** (4 × 4 min near-max / 3 min easy).

The polarised 80/20 model — ~80% of cardio volume easy, ~20% hard, little time in the moderate "grey zone" — is the most evidence-supported distribution for developing fitness sustainably.


HIIT vs steady-state and the calorie-burn truth. HIIT is **time-efficient** and excellent for VO_2max; the **"afterburn" (EPOC) adds only a modest extra burn (~6–15%)** and is widely overstated. **When calories are matched, HIIT and steady-state produce similar fat loss** — choose by goal and adherence. For fat loss specifically, **total daily movement (NEAT/steps) usually outweighs either cardio modality** as a calorie lever.

Estimating calorie burn: kcal/min ≈ METs × 3.5 × bodyweight(kg) / 200. A MET table lets you estimate the cost of any activity.

The interference effect. Large volumes of endurance (especially high-impact running) can **blunt strength and hypertrophy** via competing molecular signalling (**AMPK vs mTOR**) and shared fatigue — but it's **manageable**: separate sessions, prioritise the main goal, prefer low-impact cardio (cycling) when lifting is the priority, and keep endurance modest.

◆ Key Points

- **VO_2max is among the strongest mortality predictors** — build it deliberately.
- **Two engines: Zone 2 base + high-intensity intervals** (Norwegian 4×4).
- **Polarised 80/20** distribution develops fitness best.
- **EPOC/"afterburn" is modest**; HIIT ≈ steady-state for fat loss when calories matched.
- **kcal/min ≈ METs × 3.5 × kg / 200.**
- **Interference effect is real but manageable** — separate, prioritise, go low-impact.



Higher cardiorespiratory fitness tracks with markedly lower mortality (Mandsager et al.). Schematic shape.

9.1 Why cardiovascular fitness is non-negotiable

VO_2max integrates the health of your heart, lungs, blood, vasculature, and muscle mitochondria into one number — the maximal rate at which your body can take up and use oxygen. Because it reflects the whole oxygen-delivery-and-utilisation chain, it is an extraordinarily powerful health metric. In the Cleveland Clinic cohort of ~122,000 patients, **higher cardiorespiratory fitness tracked with lower mortality across the entire range, with no upper limit of benefit**, and being **unfit carried risk comparable to or exceeding smoking, diabetes, or established heart disease** (Chapter 2). Beyond mortality, good conditioning improves recovery between resistance sessions, supports body composition, sharpens cognition, and preserves the functional capacity that keeps you independent with age. The goal isn't to become an endurance athlete — it's to **move off the bottom of the fitness distribution and keep climbing**, because that's where the largest health returns live.

9.2 The two-engine model

Cardiovascular fitness has two trainable components, and an effective program develops both:

◆

Chapter 10 — Recovery, Soreness, Sleep & Overtraining

▣ Active Summary

The core idea. You don't grow or get fitter *during* training — you grow during **recovery** from it (the SFRA model, Chapter 4). Training provides the stimulus; recovery converts it into adaptation. Neglect recovery and even a perfect program fails. The dominant levers are **sleep, nutrition, and fatigue management** — not gadgets.

Soreness (DOMS) is a poor signal. Delayed-onset muscle soreness comes from **mechanical microdamage and inflammation, not lactic acid**, and is **not a reliable marker of a good workout or of growth.** The **repeated-bout effect** — you stop getting sore as you adapt, yet keep growing — proves soreness and hypertrophy are dissociable. **Don't chase soreness.**

Sleep is the single most powerful recovery tool. Chronic short sleep **lowers testosterone, raises cortisol, impairs glucose handling, blunts muscle protein synthesis, increases injury risk, and shifts dieting weight loss toward lean tissue.** Deep sleep also drives the brain's **glymphatic clearance** of metabolic waste. Target **7–9 hours** on a consistent schedule.


Deloads (planned easy weeks ~every 4–8 weeks) clear accumulated fatigue and let supercompensation surface (Chapters 5, 8).

Recovery modalities — evidence: massage/foam rolling help soreness modestly; **chronic post-lifting cold-water immersion blunts hypertrophy/strength adaptations** (use sparingly when building muscle); sauna/heat have cardiovascular and possible adaptive benefits; **chronic high-dose NSAIDs may blunt training adaptations.** Most gadgets are minor next to sleep and nutrition.

Overreaching vs overtraining: brief planned overreaching is useful; **prolonged non-functional overreaching and overtraining syndrome** (persistent performance drop, disturbed sleep/mood/appetite, raised resting HR, **suppressed HRV**) require real rest. Monitor with resting HR and HRV trends.

◆ Key Points

- **Adaptation happens in recovery** — sleep and nutrition are the master levers.
- **Soreness ≠ growth** (it's damage/inflammation; repeated-bout effect proves the disconnect).
- **Sleep 7–9 h** — it governs hormones, recovery, body composition, and brain clearance.
- **Deload every 4–8 weeks** to convert fatigue into adaptation.
- **Don't ice routinely after lifting** (blunts gains); don't rely on chronic NSAIDs.
- **Watch for overtraining** — falling performance + rising resting HR + dropping HRV.



The supercompensation model: a stressor dips capacity, then recovery rebuilds it slightly higher.

10.1 Recovery is where adaptation happens

The SFRA loop (Chapter 4) bears repeating because it reframes recovery from an afterthought into half the equation: **Stimulus → Fatigue → Recovery → Adaptation.** Training imposes a demand and generates fatigue; **recovery** is the phase in which fatigue dissipates and the body rebuilds slightly above baseline. The actual remodelling of muscle, the mitochondrial biogenesis, the neural consolidation — all happen *between* sessions, fuelled by sleep and nutrition. This is why two people doing the identical program can get very different results: the one who recovers better adapts better. Recovery is not passive downtime; it is when the training "pays off," and it is as programmable as the training itself.

10.2 Soreness (DOMS) — a misleading signal

Delayed-onset muscle soreness (DOMS) peaks roughly **24–72 hours** after unfamiliar or eccentric-heavy training. Its causes are **mechanical microdamage to muscle fibres and the subsequent inflammatory repair response** — **not lactic acid** (lactate clears within an hour of exercise and has nothing to do with next-day soreness, a stubborn myth). Critically, **DOMS is not a reliable indicator of a productive workout or of muscle growth.** The decisive evidence is the **repeated-bout effect**: the second time you perform a movement, you're far less sore, yet you continue to grow and progress. Soreness reflects *novelty and damage*, not stimulus quality. Chasing soreness — picking exercises or methods because they "destroy" you — is a mechanistic error (Chapter 4): it maximises the byproduct (damage) while adding recovery cost, not the driver (tension). **Program for progressive tension and recoverable fatigue, not for soreness.** Some soreness is normal, especially with new movements; its absence does not mean you didn't train hard enough.

PART III — NUTRITION & BODY COMPOSITION

Chapter 11 — Energy Balance, Weight Loss & Fat Loss (incl. TDEE, FFMI & lean mass)

▣ Active Summary

The core idea. Changing body fat comes down to **energy balance** — the long-run difference between energy consumed and energy expended. The first law of thermodynamics holds: **to lose fat you need a sustained energy deficit; to gain tissue you need a surplus.** Food quality, protein, fibre, and behaviour matter enormously — but they matter largely *because* they affect how easily you sustain the right energy balance and what *kind* of tissue you gain or lose, not because they suspend the energy equation.

Estimate your needs. Calculate **BMR** with the **Mifflin–St Jeor equation**, multiply by an **activity factor** to get **TDEE** (total daily energy expenditure), then set a deficit or surplus from there.

Rate matters. For fat loss, a deficit of ~**10–25% of TDEE** (≈300–700 kcal/day) drives sustainable loss of about **0.5–1% of body weight per week**; leaner people should go slower. For muscle gain, a **modest** surplus (~5–15%) limits fat gain — bigger surpluses just add fat, not muscle.


Protect lean mass. In a deficit, without countermeasures, **up to ~30–40% of weight lost can be lean tissue.** The protective triad: **high protein, resistance training, and adequate sleep** (plus a moderate rather than crash deficit).

Metabolic adaptation is real. As you lose weight, TDEE falls *more* than the lost mass predicts (reduced **NEAT**, hormonal shifts) — manage with **diet breaks, refeeds, and reverse dieting** rather than ever-deeper restriction.

Body-composition math. FFM (fat-free mass) = weight × (1 − bodyfat%); **FFMI = FFM(kg) / height(m)²**; **normalised FFMI = FFMI + 6.1 × (1.8 − height_m)**. The drug-free ceiling is around **FFMI 25** (Kouri[4] 1995). Judge progress by **composition and waist-to-height ratio (<0.5)**, not the scale alone.

◆ Key Points

- **Fat loss requires a sustained deficit; tissue gain requires a surplus** — thermodynamics holds.
- **BMR (Mifflin–St Jeor) × activity factor = TDEE**; set deficit/surplus from there.
- **Lose ~0.5–1%/week; gain on a *modest* surplus** — bigger isn't better.
- **Protect muscle: protein + resistance training + sleep + moderate deficit.**
- **Metabolic adaptation** lowers TDEE more than expected — manage with diet breaks, not crash dieting.
- **FFMI = FFM/height²; natural ceiling ≈ 25.** Track composition, not just weight.



Body-weight change is governed by energy balance — a sustained tilt toward 'out' drives fat loss.

11.1 The energy-balance equation, properly stated

Body energy stores change according to **(energy in) − (energy out)** over time. This is not a controversial claim — it's conservation of energy. What people get wrong is treating "energy out" as a fixed number. It isn't. **Total Daily Energy Expenditure (TDEE)** has four components, and they vary:




Figure 18

- **BMR/RMR (basal/resting metabolic rate, ~60–70%):** energy to keep you alive at rest — organs, brain, basic cellular function. Larger bodies and more lean mass raise it.
- **TEF (thermic effect of food, ~10%):** energy spent digesting and processing food. **Protein has by far the highest TEF** (~20–30% of its calories), which is part of why high-protein diets aid fat loss.
- **EAT (exercise activity, ~5–10%):** your deliberate workouts. Smaller than most people assume — you cannot reliably "out-train" a poor diet.
- **NEAT (non-exercise activity thermogenesis, ~15–30%):** all movement that isn't exercise — walking, standing, fidgeting, posture, gesturing. **The most variable component**, differing by hundreds of calories between individuals and **dropping silently during a diet** (a key driver of metabolic adaptation — 11.5). **Tracking steps protects NEAT.**

The practical lesson: **fat loss is driven more by total daily movement (NEAT/steps) and diet than by your workouts**, and "energy out" is partly behavioural and adaptive, not a constant.

Chapter 12 — Protein & Macronutrients for Muscle

▣ Active Summary

The core idea. After total energy (Chapter 11), **protein is the most important nutritional variable for building and keeping muscle**, followed by sufficient carbohydrate to fuel training and enough fat for hormones and health. Get protein and total energy right and the rest is fine-tuning.

Protein target. The point of diminishing returns for muscle gain is around **1.6 g/kg/day** (Morton[1] et al. meta-analysis, *BJSM* 2018); the practical range is **1.6–2.2 g/kg/day.** When **dieting or very lean**, go higher — up to **~2.4–3.1 g/kg of fat-free mass** — to protect muscle (Chapter 11).


Distribution. Spread protein across **3–5 meals of ~0.4 g/kg each**, hitting the **leucine threshold (~2.5–3 g leucine per meal)** that triggers muscle protein synthesis. Total daily protein matters most; distribution is optimisation.

Quality. Complete proteins (whey, dairy, egg, meat, fish) are richer in leucine and more digestible per gram than most plant proteins; **plant-based eaters should consume more total protein and combine sources.**

Carbohydrate fuels moderate-to-high-intensity training and aids recovery/glycogen — roughly **3–7 g/kg/day** depending on volume; not strictly required for fat loss but supports performance. **Fat** is essential for hormone production — keep a floor of **~0.5–1 g/kg/day**; very-low-fat diets can lower testosterone.

◆ Key Points

- **Protein ~1.6–2.2 g/kg/day** for muscle; **up to ~2.4–3.1 g/kg FFM** when dieting/lean.
- **Spread across 3–5 meals (~0.4 g/kg each), hit ~2.5–3 g leucine/meal.**
- **Total daily protein matters most**; distribution and quality are optimisation.
- **Carbs (3–7 g/kg) fuel training; fat (≥0.5–1 g/kg) protects hormones.**
- **Plant-based: eat more total protein and combine sources.**



Per-meal muscle protein synthesis rises then plateaus around ~0.4 g/kg. Schematic.

12.1 The protein dose-response

Protein supplies the amino-acid building blocks for muscle and is the macronutrient most directly tied to building and retaining it. The landmark synthesis is **Morton et al. (2018)**, a meta-analysis of 49 studies: protein intake augments resistance-training gains in muscle and strength, with the benefit **plateauing around 1.6 g/kg of body weight per day** (with a confidence interval extending toward ~2.2). Beyond that, more protein isn't harmful but yields little additional muscle for most people. So the **practical muscle-building range is 1.6–2.2 g/kg/day** — the upper end as a comfortable buffer that also aids satiety.

Two situations justify going **higher**: - **Energy deficits** (dieting): higher protein protects muscle when calories are scarce (Chapter 11). - **Older adults**: **anabolic resistance** (a blunted muscle-protein-synthesis response — Chapter 4) raises the requirement; older trainees benefit from the higher end and per-meal doses.

◆

12.2 Per-meal dosing and the leucine threshold

Muscle protein synthesis (MPS) is stimulated meal by meal and follows a **"muscle-full" effect**: beyond roughly **0.4 g/kg per meal** (~25–40 g of quality protein for most), additional protein in that single sitting is largely oxidised rather than used to build muscle. The trigger for the MPS response is the essential amino acid **leucine** — each meal should supply roughly **2.5–3 g of leucine** to maximally "switch on" synthesis (Areta[2] et al. 2013; Witard, Tipton).

The practical implication: **distribute protein across 3–5 feedings** through the day rather than eating it all in one or two large meals — this keeps MPS maximally stimulated more often. A useful pattern is **~0.4 g/kg per meal across 4 meals**, easily reaching daily targets while hitting the leucine threshold each time.

Chapter 13 — Diet Frameworks (and the carnivore question)

▣ Active Summary

The core idea. Once total energy and protein are set (Chapters 11–12), the **dietary "framework" you choose matters far less than people think — and matters mostly through adherence.** When calories and protein are matched, **no macronutrient ratio is metabolically magic for fat loss** (DIETFITS, Gardner[1] 2018; metabolic-ward studies). The diets that "win" in real life win on **satiety, simplicity, and sustainability**, not special metabolic effects.

For health and longevity specifically, the best hard-outcome evidence supports the **Mediterranean pattern** (PREDIMED, *NEJM* 2018: ~30% reduction in major cardiovascular events) and, more broadly, **whole-food, fibre-rich, plant-forward patterns with adequate protein.**

Low-carb/keto is an effective fat-loss and glycaemic tool, but its advantage largely disappears when protein and calories are matched, and it **raises LDL/ApoB sharply in some people** ("lean-mass hyper-responders") — a cardiovascular caution (Chapter 16).


Intermittent fasting / time-restricted eating is a **calorie-control and adherence tool**, not a unique fat-loss mechanism when calories are matched.

The carnivore diet has **no long-term outcome evidence**, eliminates fibre and plant compounds, and commonly causes **large rises in LDL/ApoB** — its short-term benefits are elimination-diet and calorie effects, not meat being uniquely healthful. **It is not a defensible longevity diet on current evidence.**

The honest bottom line: pick the whole-food pattern you can sustain that hits your protein and energy targets, leans Mediterranean for health, and includes plenty of fibre and plant variety.

◆ Key Points

- **Adherence, not macro ratio, decides fat-loss success** when protein/calories are matched.
- **Mediterranean pattern has the strongest hard-outcome longevity evidence.**
- **Keto/low-carb works but watch ApoB**; **fasting/TRE is a calorie tool, not magic.**
- **Carnivore: no long-term evidence, no fibre, often high ApoB — not a longevity diet.**
- **Best diet = sustainable + whole-food + adequate protein + fibre-rich + Mediterranean-leaning.**



Named diets differ in food rules but share one mechanism for fat loss: sustained energy deficit (Gardner DIETFITS).

13.1 The adherence principle

A vast amount of dietary tribalism evaporates in the face of one finding: **when researchers match calories and protein, the macronutrient ratio has little independent effect on fat loss.** The **DIETFITS trial** (Gardner et al., *JAMA* 2018) randomised people to healthy low-fat vs healthy low-carb diets for 12 months and found **no significant difference in weight loss** between them. Tightly controlled **metabolic-ward studies** (Kevin Hall and colleagues) confirm that, calories equal, low-carb and low-fat diets produce essentially equivalent fat loss; any small differences favour neither consistently.

What this means: **the "best diet" for fat loss is the one you'll actually stick to.** Diets succeed in free-living conditions because of **satiety** (protein and fibre keep you full), **simplicity** (easy rules you'll follow), and **sustainability** (fits your life, culture, and preferences) — not because of metabolic sorcery. This is liberating: you can choose a framework based on what works *for you* rather than chasing a mythical optimal macro split.

◆

13.2 The Mediterranean pattern — the longevity benchmark

For *health and longevity outcomes* (as opposed to just fat loss), one pattern stands above the rest in evidence quality: the **Mediterranean diet** — abundant **vegetables, fruits, legumes, whole grains, nuts, olive oil, and fish**, moderate dairy and poultry, low red/processed meat and refined sugar. The landmark **PREDIMED trial** (Estruch[2] et al., *NEJM* 2018) randomised high-risk adults to a Mediterranean diet (supplemented with extra-virgin olive oil or nuts) vs a control low-fat diet and found roughly a **30% reduction in major cardiovascular events** — a rare hard-outcome RCT result for a dietary pattern. Large cohort studies consistently associate Mediterranean-style eating with lower all-cause and cardiovascular mortality, less cognitive decline, and reduced diabetes risk. It works through multiple levers: high fibre and polyphenols, healthy fats, low refined carbohydrate, and an anti-inflammatory profile (Chapter 1's inflammaging). **If you want an evidence-based default for long-term health, this is it.**

Chapter 14 — Insulin: How the Master Storage Hormone Works, and How It Breaks

▣ Active Summary

The core idea. Insulin is the body's *"fed-state"* signal — the hormone that tells cells to **take up fuel and store it**. When you eat, insulin rises and does three things at once: it drives glucose out of the blood and into muscle and fat (via **GLUT4**), it switches on storage (glycogen, protein, and fat synthesis), and it switches **off** fuel release (it blocks fat breakdown and liver glucose production). Insulin resistance is the progressive failure of this signal in some tissues while it keeps working in others — and that *selective* failure, not a global shutdown, is what produces the paradox of high blood sugar **and** a fatty, fat-storing body at the same time.

How the signal travels. Insulin binds a receptor that is a **tyrosine kinase**; the receptor phosphorylates **IRS-1**, which activates **PI3K**, generating PIP_3, which recruits and activates **AKT (PKB)**. AKT is the master metabolic switch: it moves **GLUT4** to the cell surface, activates glycogen synthesis (by shutting off GSK3), turns on protein synthesis (mTOR), turns **off** liver gluconeogenesis (by evicting FOXO1 from the nucleus), and turns **on** fat synthesis (SREBP-1c). A second, separate branch — **the MAPK/ERK pathway** — carries insulin's growth (mitogenic) signals and is *not* the metabolic branch.

Insulin and fat. Insulin is powerfully **pro-storage**: it activates lipogenesis and **inhibits hormone-sensitive lipase (HSL)** and ATGL, so fat stops leaving the fat cell. It also raises **malonyl-CoA**, which blocks **CPT1** — the gatekeeper that lets fat into the mitochondria — so **fat-burning is switched off while insulin is high**. This "malonyl-CoA switch" is the hinge between burning fat and storing it.

How fat is burned (for contrast). To be oxidised, a fatty acid is activated to **fatty acyl-CoA**, then carried into the mitochondrion by the **carnitine shuttle** (**CPT1 → carnitine-acylcarnitine translocase → CPT2**). Inside, **β-oxidation** chops it into **acetyl-CoA**, which feeds the TCA cycle and the electron transport chain. CPT1 is the rate-limiting, insulin-regulated step.

How it breaks. Insulin resistance begins when fuel is chronically oversupplied. Fat that can't be stored safely spills into **muscle and liver** (ectopic fat), where lipid intermediates (**diacylglycerol → PKCθ; ceramides**) and **inflammatory signalling** (TNF-α, IL-6 → JNK/IKK) put an inhibitory *serine* phosphorylation on IRS-1, jamming the AKT branch. Crucially, the **lipogenic branch often stays sensitive** — so the liver keeps making fat even as it ignores insulin's command to stop making glucose. The result is **fasting hyperglycaemia + fatty liver + high triglycerides**.

The central paradox — glucose can't enter cells, yet it becomes fat *more* easily. Glucose is not blocked everywhere; it is **diverted**. **Muscle** (which normally handles ~80% of a glucose load) fails first, so the carbohydrate is shunted to the **liver** — whose **lipogenic branch is still insulin-sensitive** and is being flogged by high insulin. The liver converts that glucose into **fat** (de novo lipogenesis → VLDL), which is deposited in adipose tissue and in the liver itself. Meanwhile **adipose tissue is itself insulin resistant**, so it **fails to suppress lipolysis** — **FFA flux rises**, feeding **lipotoxicity**. Fat mass still expands because inflow (hepatic lipogenesis + dietary fat) exceeds that elevated outflow: a **futile cycle**, not a one-way valve. (Adipose GLUT4 is *also* reduced — the fat is not made from glucose entering the fat cell; it arrives **pre-made by the liver**.)

Chapter 15 — The Mitochondria: The Cellular Powerhouse, and How CoQ10, NAD^+, NMN & NR Fit In

▣ Active Summary

The core idea. The mitochondrion is where fuel is finally converted into usable energy. The acetyl-CoA produced by burning carbohydrate and fat enters the **TCA cycle**, which strips off electrons and loads them onto two carriers — **NADH** and **$FADH_2$**. Those carriers deliver their electrons to the **electron transport chain (ETC)**, a series of protein complexes that use the energy to pump protons across the inner membrane, creating a gradient that spins **ATP synthase** to make **ATP**. Everything else in this chapter — CoQ10, NAD^+, NMN, NR — is about keeping this machine supplied and running.

The electron transport chain. Electrons flow **NADH → Complex I → CoQ10 → Complex III → cytochrome c → Complex IV → oxygen** (which is why we breathe: oxygen is the final electron acceptor, becoming water). **Coenzyme Q10 (ubiquinone)** is the mobile carrier that shuttles electrons from Complexes I and II to Complex III, and doubles as a lipid-soluble antioxidant. **Statins** lower CoQ10 (they block the same pathway that makes it), which is the rationale for CoQ10 in statin-associated muscle symptoms.

NAD^+ — the master coenzyme. NAD^+ is the electron carrier that makes energy production possible: it is *reduced* to NADH in glycolysis, the TCA cycle, and β-oxidation, then *re-oxidised* back to NAD^+ at **Complex I**. This NAD^+/NADH cycling is the beating heart of metabolism. But NAD^+ is also *consumed* (not just cycled) by three families of enzymes: the **sirtuins** (which switch on mitochondrial biogenesis and stress defence — SIRT1 and SIRT3), the **PARPs** (DNA repair), and **CD38** (immune signalling). NAD^+ **falls with age**, which is the entire rationale for supplementing its precursors.

NMN and NR. Nicotinamide riboside (NR) and **nicotinamide mononucleotide (NMN)** are vitamin-B3 molecules that the body converts, through the **salvage pathway**, into NAD^+. They *reliably raise NAD^+* in humans and activate the NAD^+-dependent sirtuins — which deacetylate and switch on **PGC-1α**, the master regulator of **mitochondrial biogenesis**. The honest verdict (as in the supplement chapters of Part V): the biochemistry is real and the NAD^+ rise is real, but **no human trial has yet shown they extend healthspan or lifespan** — they change a biomarker, not (yet) a proven outcome.

Mitochondrial biogenesis. You are not stuck with the mitochondria you have. **PGC-1α**, activated by **AMPK** (energy stress), **SIRT1** (NAD^+), and above all **exercise**, drives the building of new mitochondria; **mitophagy** clears the damaged ones. This is why **endurance training is the most powerful mitochondrial "supplement" that exists** — it raises both the number and the quality of your mitochondria in a way no capsule matches.

The liver, gluconeogenesis, and hormones. The mitochondrion is also central to **making** glucose. In fasting, the liver builds glucose from lactate, amino acids, and glycerol — and the first committed step, **pyruvate → oxaloacetate (pyruvate carboxylase)**, happens *inside the mitochondrion*. **Glucagon and cortisol** drive this; **insulin normally suppresses it** — and in insulin resistance, this suppression fails, which is why the fasting blood sugar rises.

Nutrition ties it together. The **fed state** (high insulin, high malonyl-CoA) stores fuel and blocks fat oxidation; the **fasted / low-carbohydrate / exercised state** (glucagon, AMPK, rising NAD^+) burns fat, makes ketones, and builds mitochondria. Overfeeding overwhelms the machine — the mitochondrial overload that drives insulin resistance. Every mitochondrial strategy is really about **matching fuel supply to oxidative capacity, and building more capacity.**

PART IV — ORGAN-SYSTEM HEALTH

Chapter 16 — Cardiovascular Health

▣ Active Summary

The core idea. Cardiovascular disease is the **leading cause of death worldwide**, and most of it is **preventable.** The dominant disease process is **atherosclerosis** — the build-up of plaque in artery walls — and its single most important causal driver is **apoB-containing lipoproteins (LDL and related particles).** Control the modifiable cardiovascular risk factors and you prevent the disease that most often ends or disables a long life.

The causal core — ApoB. Atherosclerosis is **caused** by apoB-carrying lipoproteins infiltrating the artery wall; the evidence (Mendelian randomisation + drug RCTs) is among the strongest in medicine (Ference[1] et al. consensus, *Eur Heart J* 2017). **The lower your lifetime cumulative apoB/LDL exposure, the lower your risk** — and **ApoB is a better risk marker than standard LDL-C**, because it counts atherogenic *particles*. **Lp(a)** is a partly-genetic, independent added risk worth measuring once.


The modifiable risk stack (rough order): don't smoke → lower apoB/LDL → control **blood pressure (~<120–130/80)** → maintain **fitness and healthy body composition** → manage **glucose/insulin** → sleep (treat apnoea).

Blood pressure is the single biggest *population* driver of cardiovascular death; lifestyle plus medication as needed.

Exercise is broadly cardioprotective (endothelial function, BP, lipids, glucose, autonomic tone); both aerobic and resistance training help. A minor caution: heavy straining causes large transient BP spikes (Valsalva) — generally safe for healthy people, managed in uncontrolled hypertension.

◆ Key Points

- **Atherosclerosis is caused by apoB lipoproteins** — lower lifetime exposure = lower risk.
- **ApoB beats LDL-C as a risk marker; measure Lp(a) once.**
- **Blood pressure** is the biggest population driver — target ~<120–130/80.
- **The risk stack:** no smoking → apoB → BP → fitness/body comp → glucose → sleep.
- **Exercise is cardioprotective** through many channels.



The heart and great vessels. Gray's Anatomy (1918) — public domain.

16.1 The disease: atherosclerosis

Cardiovascular disease — heart attacks, most strokes, peripheral artery disease — is overwhelmingly the result of **atherosclerosis**, a decades-long process in which **plaque accumulates within the walls of arteries.** The sequence: apoB-containing lipoprotein particles (chiefly **LDL**) penetrate the inner artery wall (the endothelium), become trapped and oxidised, trigger an **inflammatory response**, and accumulate as cholesterol-laden plaque. Over years this narrows arteries and, critically, plaques can **rupture**, forming a clot that abruptly blocks blood flow — causing a heart attack or stroke. The disease is **silent for decades** before the first event, which is why prevention (acting on the causes long before symptoms) is everything.

Chapter 17 — Bone & Musculoskeletal Health

▣ Active Summary

The core idea. Bone is **living, adaptive tissue** that strengthens in response to mechanical load (**Wolff's law**) and weakens without it. Bone strength and muscle strength together form the **musculoskeletal foundation of a long, independent life** — and the fractures that cause much of the disability and mortality in older age are largely **preventable** through loading, nutrition, and falls prevention.

Peak and decline. Peak bone mass is reached by roughly the late 20s–30s; after that the goal is to **minimise loss.** Loss accelerates in **postmenopausal women** (oestrogen withdrawal) and in older men, leading to **osteopenia** and **osteoporosis** — silent until a fracture occurs.


The most effective loading: progressive resistance training plus **high-impact loading** (jumping, running, hopping). The **LIFTMOR trial** (Watson[1] et al., *JBMR* 2018) showed that even **heavy resistance and impact training is safe and improves bone density** in postmenopausal women with low bone mass — overturning old "go light, bones are fragile" advice. Swimming and cycling, though great for fitness, are **not osteogenic** (no impact).

Nutritional foundations: calcium (~1000–1200 mg/day, food first), vitamin D (maintain 25-OH-D ~30–50 ng/mL), adequate protein, vitamin K2 (emerging), and magnesium. Importantly, **higher protein is bone-protective, not harmful** — the old "protein leaches calcium from bone" claim is a myth.

Falls prevention — balance and strength training — prevents the falls that cause the fractures that actually drive morbidity and mortality in the elderly. **Connective tissue (tendon, ligament, cartilage)** also adapts to loading; movement is protective for joints.

◆ Key Points

- **Bone adapts to load** (Wolff's law); use it or lose it.
- **Resistance + impact training** build/preserve bone; **swimming/cycling don't.**
- **Heavy training is safe and effective** even in older low-bone-mass populations (LIFTMOR).
- **Calcium + vitamin D + protein + K2 + magnesium** are the nutritional base.
- **Protein protects bone** — the "protein harms bone" idea is wrong.
- **Falls prevention (balance + strength)** stops the fractures that matter.



Bone architecture and growth — living tissue that remodels under load. Gray's Anatomy (1918) — public domain.

17.1 Bone is living, adaptive tissue

Bone is not inert scaffolding — it is **metabolically active, living tissue** in constant turnover, continuously broken down by **osteoclasts** and rebuilt by **osteoblasts** (the **remodelling** process). Crucially, bone **adapts to the mechanical demands placed on it** — **Wolff's law**: bone subjected to load lays down more mineral and becomes denser and stronger where stress is applied, while unloaded bone (bed rest, spaceflight, sedentary living) demineralises and weakens. This is exactly analogous to muscle: **use it or lose it.** The practical consequence is that **mechanical loading is the primary stimulus for building and maintaining bone**, and the strain *magnitude and rate* (how heavy and how fast the load) matter more than endurance volume.

◆

17.2 Peak bone mass and age-related loss

Bone mass builds through childhood and adolescence, **peaking by roughly the late 20s to mid-30s.** The higher your peak, the more reserve you carry into later life. After the peak, **bone is gradually lost**, and the rate accelerates in specific situations:

- **Postmenopausal women:** the loss of **oestrogen** (a key bone-protective hormone) at menopause causes **rapid bone loss** in the following years — the main reason osteoporosis is more common in women.
- **Older men:** slower but real decline, tied partly to falling testosterone (which converts to oestrogen in bone).

Progressive loss leads to **osteopenia** (low bone mass) and then **osteoporosis** (bone fragile enough to fracture from minor trauma). These conditions are **silent** — there are no symptoms until a fracture happens, often at the **hip, spine, or wrist.** Hip fractures in particular are devastating in older adults, frequently triggering a cascade of lost independence, complications, and elevated mortality. **Building a high peak in youth and defending bone aggressively with age** is the strategy.

◆

Chapter 18 — Brain & Mental Health

▣ Active Summary

The core idea. The brain is an organ that responds to the same levers as the rest of the body — and **exercise, sleep, nutrition, and social connection are among the most powerful tools available for both mental wellbeing and long-term cognitive health.** What's good for the heart (Chapter 16) is good for the brain, because the brain depends on healthy vasculature.

Exercise for mood. Physical activity is **one of the most reliable non-drug interventions for depression and anxiety.** Large reviews (Schuch[1] et al. 2016; the Singh[2] et al. umbrella review, *BJSM* 2023) find exercise has effects on depression **comparable to, and additive with, psychotherapy and medication.** Both aerobic and resistance training help; even modest doses work, and higher intensity tends to give larger short-term mood effects.

Mechanisms span **BDNF and neuroplasticity, monoamine and endocannabinoid signalling, reduced neuroinflammation, improved sleep, and psychological factors** (self-efficacy, routine, mastery).


Sleep is foundational and bidirectional with mental health (Chapter 10).

Cognitive longevity. There's no proven "anti-Alzheimer's pill," but the **modifiable dementia risk factors** (Lancet Commission[3]) are substantial, and **fitness, resistance training, vascular-risk control, sleep, social/intellectual engagement, and hearing care** are the best-supported protectors of the aging brain.

Important: these tools are **powerful complements to, not replacements for, professional mental-health care.** Anyone struggling persistently deserves support from a qualified professional.

◆ Key Points

- **Exercise rivals and adds to standard treatments for depression/anxiety.**
- Mechanisms: **BDNF/neuroplasticity, monoamines, less neuroinflammation, better sleep, self-efficacy.**
- **What's good for the heart is good for the brain** — vascular health drives cognitive longevity.
- **Sleep is foundational** and bidirectional with mental health.
- These are **complements to professional care, not substitutes.**



The human brain. Gray's Anatomy (1918) — public domain.

18.1 Exercise as one of the most reliable mood interventions

Among all the non-pharmacological tools for mental health, **exercise has some of the strongest and most consistent evidence.** This isn't merely "you feel better after a workout" — controlled trials and large meta-analyses show **clinically meaningful reductions in depressive and anxiety symptoms** with regular physical activity. The **Schuch et al. (2016)** meta-analysis found robust antidepressant effects; the **Singh et al. umbrella review (*BJSM* 2023)**, synthesising many reviews, concluded that exercise is **highly effective for depression, anxiety, and psychological distress**, with effects **comparable to** psychotherapy and medication in many contexts and **additive** when combined with them. The benefit appears across modalities and doses, with **higher intensities** tending to produce **larger short-term mood improvements**, though consistency matters more than intensity for lasting benefit. Exercise is not a cure-all and not a replacement for treatment of serious illness — but as a **high-value, low-risk, broadly beneficial pillar of mental wellbeing**, it is hard to overstate.

◆

18.2 How exercise benefits the brain — mechanisms

The mood and cognitive benefits of exercise arise through multiple converging pathways:

Chapter 19 — Liver Health

▣ Active Summary

The core idea. The liver is the body's **metabolic hub** — it processes nutrients, synthesises proteins and bile, stores glycogen and vitamins, and metabolises drugs, alcohol, and toxins. The dominant modern liver disease is **MASLD** (metabolic dysfunction-associated steatotic liver disease, formerly **NAFLD**) — fat accumulation in the liver tied to **insulin resistance and visceral adiposity** — and it is largely a **lifestyle/metabolic** problem with a **lifestyle/metabolic** solution.

The treatment is metabolic. A **7–10%**[1] **body-weight loss can resolve liver steatosis and improve fibrosis**; **exercise improves liver fat even without weight loss**; and reducing **refined carbohydrate, added sugar (especially fructose), and alcohol** directly helps.


Alcohol is a direct hepatotoxin with **dose-dependent** harm and no clearly "safe" level for the liver.

Supplement and drug caution. The liver metabolises most oral compounds, and several can injure it: **oral 17α-alkylated anabolic steroids are notably hepatotoxic** (Chapter 35), as can be **high-dose green-tea extract, certain herbal/"detox" products, and excess vitamin A.** Conversely, **coffee is consistently associated with lower liver-disease progression.**

The liver is resilient and regenerative — caught early, MASLD is highly reversible. Protect it by **maintaining healthy body composition, exercising, moderating alcohol and sugar, and being cautious with hepatotoxic supplements.**

◆ Key Points

- **MASLD/NAFLD** (fatty liver) is driven by **insulin resistance and visceral fat** — and is **reversible.**
- **7–10% weight loss** can resolve steatosis; **exercise helps independent of weight loss.**
- **Cut added sugar/fructose and alcohol**; **coffee is protective.**
- **Oral 17α-alkylated steroids and some supplements are hepatotoxic** — be cautious.
- The liver is **regenerative** — early action reverses most fatty-liver disease.



The liver. Gray's Anatomy (1918) — public domain.

19.1 The liver — the metabolic hub

The liver is arguably the body's busiest metabolic organ. Its roles include **processing nutrients** absorbed from the gut (glucose, fats, amino acids), **storing and releasing glycogen** to regulate blood sugar, **synthesising** proteins (albumin, clotting factors), **producing bile** for fat digestion, **storing vitamins and minerals**, and **metabolising and clearing** drugs, hormones, alcohol, and metabolic waste. Because so much passes through it, the liver is exposed to whatever you eat, drink, and take — and its health both reflects and influences whole-body metabolic status. It is also remarkably **resilient and regenerative**, which is good news: liver damage caught early is often reversible.

◆

19.2 MASLD/NAFLD — the modern epidemic

MASLD (metabolic dysfunction-associated steatotic liver disease — the updated name for non-alcoholic fatty liver disease, NAFLD) is now the **most common chronic liver condition**, affecting a large fraction of adults, paralleling the rise in obesity and type 2 diabetes. The process: excess **visceral and ectopic fat** and **insulin resistance** lead to **fat accumulation in liver cells (steatosis)**. In a subset, this progresses to **steatohepatitis**[1] **(MASH)** — fat plus inflammation and cell injury — which can advance to **fibrosis, cirrhosis, and liver failure or cancer.** Critically, MASLD is usually **silent** in early stages and is a marker of broader cardiometabolic dysfunction — people with MASLD are at elevated risk of cardiovascular disease and diabetes. It is fundamentally a **metabolic disease of energy excess and insulin resistance**, which is exactly why the solution is metabolic.

Chapter 20 — Kidney & Excretory Health

▣ Active Summary

The core idea. The kidneys are the body's **filtration and homeostasis system** — clearing waste, balancing fluid and electrolytes, regulating blood pressure, activating vitamin D, and producing the hormone that drives red-blood-cell production. Two persistent fitness myths surround them, and both are **wrong**: that **high protein damages healthy kidneys** and that **creatine harms the kidneys.** Neither is true in healthy people.

The protein myth. In people with **healthy kidneys, higher protein intake does not cause kidney disease** (Devries[1] et al. meta-analysis 2018). Protein restriction is relevant only for those with **pre-existing kidney disease.**


The creatine myth. Creatine **raises serum creatinine** — but creatinine is simply creatine's breakdown product, a **lab marker, not evidence of damage.** Creatine does **not** harm healthy kidneys; the raised reading can be misinterpreted as dysfunction.

The real kidney threats: uncontrolled high blood pressure and diabetes (the two leading causes of chronic kidney disease), **chronic NSAID overuse, dehydration, and nephrotoxic supplement megadoses or contaminated products.**

Protect your kidneys by controlling blood pressure and glucose, staying hydrated, avoiding chronic painkiller overuse, and being cautious with unregulated supplements.

◆ Key Points

- **High protein does NOT harm healthy kidneys** (Devries 2018) — restriction is only for existing kidney disease.
- **Creatine raises serum creatinine (a marker), not actual damage** — don't misread labs.
- **Real threats: hypertension, diabetes, chronic NSAIDs, dehydration, nephrotoxic supplements.**
- **Protect kidneys via BP/glucose control + hydration.**



The kidney and nephron. Gray's Anatomy (1918) — public domain.

20.1 The kidneys — filtration and homeostasis

The kidneys do far more than "make urine." They **filter the blood** (clearing metabolic waste like urea and creatinine), **balance fluid and electrolytes** (sodium, potassium, etc.), **regulate blood pressure** (via the renin-angiotensin system and fluid balance), **activate vitamin D** (to its hormonally active form — relevant to bone, Chapter 17), **maintain acid-base balance**, and **produce erythropoietin** (the hormone that stimulates red-blood-cell production). Because they handle so much of the body's homeostasis, protecting kidney function is important for whole-body health — and chronic kidney disease, like fatty liver and atherosclerosis, is often **silent until advanced.**

◆

20.2 The protein myth, debunked

Perhaps the most persistent nutrition myth in fitness is that **high-protein diets damage the kidneys.** The origin is a misapplication: in people who **already have kidney disease**, protein restriction can slow progression — and this was incorrectly generalised to healthy people. The evidence in **healthy individuals is clear**: **higher protein intake does not harm kidney function.** A meta-analysis by **Devries et al. (2018)** found no adverse effect of higher protein intake on kidney function (glomerular filtration rate) in healthy adults. What happens with higher protein is a **benign, adaptive increase in glomerular filtration** — the kidneys handling more nitrogen — **not damage.** Long-term studies of higher-protein diets show no decline in kidney function in healthy people. So the muscle-building protein intakes recommended in this book (1.6–2.2 g/kg, even higher when dieting — Chapter 12) are **safe for healthy kidneys.** The one genuine caveat: people with **existing chronic kidney disease** should manage protein under medical guidance — for them, the rules differ.

◆

Chapter 21 — Respiratory Health

▣ Active Summary

The core idea. The respiratory system delivers oxygen and removes carbon dioxide — the first link in the chain that VO_2max depends on (Chapter 9). Lung function **peaks in the 20s and declines gradually with age**, and the **single dominant accelerant of that decline is smoking** (the cause of COPD). Protecting the lungs is mostly about **avoiding inhaled toxins and staying aerobically fit.**


Lung function and training. Aerobic training **improves the efficiency of breathing and the whole oxygen-delivery chain** and reduces breathlessness, though in healthy people it doesn't dramatically change **static lung volumes** (lungs aren't a muscle you can "grow" much) — the gains come from better ventilatory efficiency, stronger respiratory muscles, and improved gas exchange and delivery downstream.

Protect the lungs: don't smoke or vape, manage **air-quality exposure**, treat **asthma/allergies**, and stay **aerobically fit.** For specific populations, **inspiratory muscle training**[1] (resisted breathing) can improve symptoms and performance.

Because respiratory fitness underpins VO_2max, and VO_2max is one of the strongest longevity predictors (Chapter 2), keeping the breathing system healthy is part of the longevity foundation.

◆ Key Points

- **Lung function peaks in the 20s; smoking/vaping is the dominant cause of decline (COPD).**
- **Aerobic training improves breathing efficiency** and the whole oxygen chain (not static lung size).
- **Protect lungs: no smoking/vaping, manage air quality, treat asthma/allergy, stay fit.**
- **Inspiratory muscle training** helps specific populations.
- Respiratory health underpins **VO_2max** and thus longevity.



The lungs and airways. Gray's Anatomy (1918) — public domain.

21.1 The respiratory system's role

Every cell needs oxygen for energy production and must dispose of carbon dioxide. The respiratory system handles the **gas-exchange end** of this: air moves into the lungs, oxygen diffuses across the **alveoli** (tiny air sacs) into the blood, and carbon dioxide diffuses out to be exhaled. This is the **first link** in the oxygen-delivery chain that ends with mitochondria using oxygen in working tissue (Chapter 9). The efficiency of breathing — driven by the **diaphragm and respiratory muscles**, the elasticity of lung tissue, and the surface area for gas exchange — partly determines how well you can supply oxygen during exertion and recovery. A healthy respiratory system is quiet, efficient, and rarely thought about; declining respiratory function shows up as breathlessness, reduced capacity, and lost endurance.

◆

21.2 Lung function across life — and the role of smoking

Lung function (measured by **FEV_1**, the volume forcibly exhaled in one second, and **FVC**, forced vital capacity) builds through youth, **peaks in the 20s**, plateaus, then **declines gradually with age** as lung tissue loses elasticity and respiratory muscles weaken. In healthy non-smokers this decline is slow and rarely limiting for normal life. The problem is **accelerated decline**, and its overwhelming cause is **smoking.**

Smoking (and vaping) damages the airways and alveoli, driving **chronic obstructive pulmonary disease (COPD)** — a progressive, irreversible loss of lung function that causes breathlessness, chronic cough, and disability, and is a leading cause of death. The rate of lung-function decline in smokers is **far steeper** than in non-smokers, and the damage to alveolar architecture (emphysema) is permanent. **Quitting at any age slows the rate of decline back toward normal** — the single most important thing anyone can do for their lungs is **not smoke or vape.** Vaping, while newer and still being studied, is **not harmless** and should not be assumed safe for the lungs.

◆

Chapter 22 — Gastrointestinal Health

▣ Active Summary

The core idea. The gut does far more than digest food — it houses **trillions of microbes (the microbiome)** that influence metabolism, immunity, inflammation, and even mood (the gut-brain axis). The **single most evidence-backed lever for gut and metabolic health is dietary fibre**, which feeds the microbiome, produces beneficial short-chain fatty acids, and is **independently associated with lower all-cause and cardiovascular mortality** (Reynolds[1] et al., *Lancet* 2019).

Fibre and diversity. Target **≥25–35 g of fibre per day** from **a wide variety of plants** — microbiome diversity (driven mainly by plant/fibre variety, the "**30+ different plant foods per week**" heuristic) is associated with better health.


Fermented foods (yogurt, kefir, kimchi, sauerkraut) may **increase microbiome diversity and lower inflammation** (Wastyk[2]/Gardner, *Cell* 2021).

Probiotic supplements have **strain- and condition-specific** benefits (e.g., certain strains for antibiotic-associated diarrhoea or IBS) — they're **not** a general health booster.

Protect the gut: eat plenty of fibre and varied plants, include fermented foods, **limit ultra-processed foods and excess alcohol**, manage stress (the gut-brain axis is real), and **avoid unnecessary antibiotics.**

◆ Key Points

- **Fibre is the master gut lever** — ≥25–35 g/day, linked to lower mortality (Reynolds 2019).
- **Microbiome diversity** comes mainly from **plant/fibre variety** ("30+ plants/week").
- **Fermented foods** boost diversity and lower inflammation (Gardner 2021).
- **Probiotics are strain-specific**, not a general tonic.
- **Limit ultra-processed food and alcohol; manage stress; avoid needless antibiotics.**



The digestive tract. Gray's Anatomy (1918) — public domain.

22.1 The gut and its microbiome

The gastrointestinal tract digests food, absorbs nutrients, and eliminates waste — but its most fascinating dimension is the **microbiome**: the **trillions of bacteria (and other microbes)**, mostly in the colon, that form a complex ecosystem with profound effects on health. These microbes **ferment dietary fibre** into **short-chain fatty acids (SCFAs** like butyrate) that nourish the gut lining and modulate metabolism and immunity; they **train and regulate the immune system** (a large fraction of which resides in the gut); they influence **inflammation** (Chapter 1's inflammaging) and **metabolism**; and they communicate with the brain via the **gut-brain axis**. A **diverse, balanced microbiome** is associated with better health, while reduced diversity and **dysbiosis** (the twelfth hallmark of aging — Chapter 1) are linked to metabolic, inflammatory, and other diseases. Much of gut health, therefore, is really about **feeding and maintaining a healthy microbial ecosystem.**

Chapter 23 — Reproductive & Hormonal Health (incl. clinical HRT/TRT)

▣ Active Summary

The core idea. Sex hormones — **testosterone** in men, **oestrogen and progesterone** in women — regulate far more than reproduction: libido, energy, mood, muscle, bone, cognition, and cardiovascular health. They **decline with age** (gradually in men, sharply at **menopause**[2] in women), and **hormone therapy is a legitimate medical treatment** where genuinely indicated — but it belongs within **monitored clinical care**, not self-prescription. *(This chapter is clinical/educational overview, not a dosing or protocol guide.)*

The HPG axis. Hormone production is governed by the **hypothalamic-pituitary-gonadal (HPG) axis** with negative feedback — which is why **exogenous hormones (TRT, anabolic steroids) suppress natural production** and fertility (Chapter 35).


Male hypogonadism[1] is diagnosed by **symptoms PLUS repeated low morning testosterone**, not numbers alone — and much "low T" is **functional** (driven by obesity, poor sleep, overtraining, stress) and **reversible with lifestyle first.** Genuine hypogonadism is appropriately treated with **TRT**, with real benefits and trade-offs (fertility suppression, erythrocytosis, monitoring needs).

Female menopausal HRT: modern reappraisal of the WHI data supports HRT for **symptom control and bone protection** with a favourable benefit/risk profile when **started near menopause onset** (the "timing hypothesis[5]") in appropriate candidates — individualised with a clinician.

Crucially, oestrogen is essential in men too (bone, lipids, libido), and **low energy availability** (extreme dieting/training) suppresses sex hormones in both sexes.

◆ Key Points

- **HPG axis with feedback** — exogenous hormones suppress natural production/fertility.
- **Male "low T" is often functional** — fix sleep, body fat, overtraining, stress FIRST.
- **TRT is legitimate for true hypogonadism** — benefits + monitoring (haematocrit, fertility, prostate).
- **Menopausal HRT** favourable when started near menopause (timing hypothesis); individualised.
- **Oestrogen matters in men**; **low energy availability suppresses hormones** in both sexes.
- This is **clinical overview, not self-prescription.**



The hypothalamus — apex of the hormonal (HPG) axis. Gray's Anatomy (1918) — public domain.

23.1 The HPG axis

Sex-hormone production is controlled by a feedback loop, the **hypothalamic-pituitary-gonadal (HPG) axis**:

Chapter 24 — Skin, Hair & Dermatological Anti-Aging

▣ Active Summary

The core idea. Skin and hair are where aging is most visible, and dermatology has a clear **evidence hierarchy** — a few interventions do most of the work, and a vast cosmetic market sells the rest. **Photoprotection is the single highest-yield anti-aging skin intervention** (UV drives the majority of visible skin aging and skin cancer), and **topical retinoids (tretinoin)** are the best-evidenced active for wrinkles and texture.

The skin anti-aging core: daily broad-spectrum sunscreen (prevents and even reverses photoaging — Hughes[1] RCT) + **a retinoid** (increases collagen, normalises cell turnover). Everything else is optimisation: **vitamin C** (antioxidant, collagen cofactor), **niacinamide** (barrier, pigment, oil), **AHAs**, and peptides (modest).


Hair loss (androgenetic): the best-evidenced therapies are **minoxidil (topical/oral)** and **5α-reductase inhibitors (finasteride/dutasteride)**; adjuncts include **microneedling, low-level laser, and PRP** (variable evidence). Treatment **maintains/regrows; stopping reverses gains.**

Oral "anti-aging" actives (collagen peptides, antioxidants) have **modest** skin evidence; **oral glutathione for "skin whitening" is poorly bioavailable and weakly evidenced**, and **IV/IM glutathione remains an off-label cosmetic practice with limited rigorous support** (Chapter 28).

Lifestyle matters too: don't smoke, protect from UV, sleep, and manage sugar/glycation — they all show on the skin.

◆ Key Points

- **Sunscreen is the #1 anti-aging skin intervention** — prevents and reverses photoaging.
- **Tretinoin is the best-evidenced topical** for wrinkles, texture, pigment.
- **Vitamin C, niacinamide, AHAs** are solid supporting actives.
- **Hair loss: minoxidil + 5α-reductase inhibitors**; treatment must continue or gains reverse.
- **Oral glutathione/skin-whitening is weakly evidenced; IV glutathione is off-label.**
- **Don't smoke; protect from UV; sleep; limit sugar (glycation).**



Skin in cross-section, with hair follicle and glands. Gray's Anatomy (1918) — public domain.

24.1 How skin ages: intrinsic vs extrinsic

Skin aging has two components: - **Intrinsic (chronological) aging** — the genetically programmed, time-dependent decline: thinning, reduced collagen and elastin production, slower cell turnover, drier skin. This happens to everyone and is relatively slow. - **Extrinsic aging** — damage from external factors, **overwhelmingly ultraviolet (UV) radiation ("photoaging")**, plus pollution, smoking, and other exposures. **Extrinsic aging accounts for the majority of *visible* skin aging** — the wrinkles, coarse texture, pigmentation, and loss of elasticity people most want to address are largely **sun damage**, not inevitable chronology.

The crucial implication: because **most visible aging is extrinsic and driven by UV**, the most powerful anti-aging strategy is **preventing and reversing photodamage** — which makes photoprotection and retinoids the foundation.

◆

24.2 Photoprotection — the highest-yield intervention

If you do one thing for your skin's long-term appearance and health, it's **daily broad-spectrum sun protection.** UV radiation drives the majority of wrinkles, pigmentation, texture changes, and loss of elasticity — and is the primary cause of **skin cancer.** The evidence is strong: a landmark **RCT (Hughes et al., *Ann Intern Med* 2013)** showed that **regular sunscreen use significantly slowed skin aging** compared to discretionary use — sunscreen doesn't just prevent cancer, it **measurably prevents (and helps reverse) photoaging.**

Practical photoprotection: **broad-spectrum SPF 30+ daily** (covering UVA and UVB), reapplied with sun exposure; plus **physical measures** (shade, hats, protective clothing, sunglasses) which are highly effective. This single habit outperforms every expensive serum for long-term skin appearance and is the **non-negotiable foundation** of any anti-aging regimen — a point you, as a cosmetic dermatologist, communicate to patients daily.

◆

PART V — SUPPLEMENTS (EVIDENCE-GRADED)

Chapter 25 — How to Read Supplement Evidence

▣ Active Summary

The core idea. The supplement industry is **enormous, under-regulated, and over-marketed.** A **small handful** of supplements have strong human evidence; the **vast majority** range from "maybe" to "wishful thinking" to "actively misleading." Before spending money or swallowing anything, you need a **framework for separating signal from marketing** — because the burden of proof is on the supplement, and most fail it.

The evidence tiers used throughout this Part: **Strong** (consistent RCTs/meta-analyses) · **Moderate** (some RCTs, mixed/limited) · **Emerging** (mechanistic or early human data) · **Weak/marketing** (popular but poorly supported).

The supplement pyramid. Training, nutrition, sleep, and body composition are **~95% of your results**; supplements are the **last ~5%** of fine-tuning. **No powder out-performs the Big Rocks** (Chapter 2). A person doing the fundamentals poorly should fix those before buying supplements.

Regulation reality: in most countries, supplements are **not** held to drug-level standards for safety, efficacy, or even **label accuracy** — products are frequently **mislabeled or contaminated** (sometimes with banned substances). **Third-party testing** (NSF Certified for Sport, Informed Sport) is essential for anyone who values label accuracy or could be drug-tested.

Watch for: funding bias, surrogate-marker hype, tiny studies, acute-effect extrapolation, and the placebo/expectancy trap.

◆ Key Points

- **Most supplements are under-evidenced**; a few are genuinely useful.
- **Tiers: Strong / Moderate / Emerging / Weak-marketing.**
- **Supplements are the last ~5%** — fix training, diet, sleep, body comp first.
- **Supplements aren't regulated like drugs** — mislabeling/contamination are common.
- **Buy third-party tested** (NSF Certified for Sport, Informed Sport).



A shelf of common supplements — of the dozens on the market, only a handful clear the evidence bar.

25.1 The supplement landscape

The global supplement market is worth tens of billions and is built on a simple, powerful psychology: the hope that a pill or powder can deliver what discipline and time otherwise require. Some supplements genuinely help — a few are among the best-studied interventions in sports science. But the **majority of the market is sold on weak evidence, clever marketing, and hope.** The honest starting position for evaluating any supplement is **skepticism**: assume it doesn't work until reasonable human evidence shows it does, because **that's where most products land.** This isn't cynicism — it's the appropriate prior given how the industry operates and how few products clear a meaningful evidence bar.

◆

25.2 The evidence tiers

This Part grades every supplement by a simple, consistent scale, so you always know how much to trust a recommendation:

Chapter 26 — Foundational Tier


▣ Active Summary

The core idea. A small number of supplements have **strong enough evidence and broad enough benefit** to be worth considering for most people who train and care about health. These are the **foundational tier** — the few that clear the bar from Chapter 25.

- **Creatine monohydrate — STRONG. ~3–5 g/day** (optional loading 20 g/day split over 5–7 days fills stores faster). The most proven sports supplement: increases strength, power, lean mass, and work capacity, with emerging cognitive and recovery benefits. **Safe long-term**; raises serum creatinine (a marker, not harm — Chapter 20).
- **Protein powder (whey/casein) — STRONG (as a food tool).** A convenient way to hit protein targets (Chapter 12). **Whey** = fast, high-leucine (good around training); **casein** = slow (good pre-sleep). ~20–40 g per serving.
- **Omega-3 (EPA/DHA) — MODERATE/STRONG. ~1–3 g/day combined EPA+DHA**; cardiovascular, triglyceride, anti-inflammatory, and possible muscle/mood benefits. Use tested, low-oxidation oils.
- **Vitamin D — MODERATE (correct deficiency).** Supplement to maintain **25-OH-D ~30–50 ng/mL** (commonly **1000–2000 IU/day**, more if deficient). Benefits clearest when correcting deficiency.
- **Magnesium — MODERATE. ~200–400 mg elemental/day** (glycinate/citrate absorb well); supports sleep, neuromuscular function, and glucose handling; many people under-consume.

◆ Key Points

- **Creatine (3–5 g/day):** the single most proven supplement — strength, power, lean mass, cognition.
- **Protein powder:** a *tool* to hit protein targets, not "anabolic" beyond being protein.
- **Omega-3 (1–3 g/day EPA+DHA):** cardiovascular, triglyceride, anti-inflammatory benefits.
- **Vitamin D:** correct deficiency to ~30–50 ng/mL.
- **Magnesium (200–400 mg):** sleep, muscle, glucose; commonly under-consumed.



The foundational five — the supplements that clear the evidence bar for most people (Kreider; Jäger; Manson).

26.1 Creatine monohydrate — the most proven supplement

If you take only one supplement, it should be **creatine monohydrate** — the most-researched, most-effective, and safest sports supplement available (ISSN position stand, Kreider[1] et al. 2017).

What it is and how it works. Creatine is a compound stored in muscle as **phosphocreatine**, which rapidly regenerates **ATP** (cellular energy) during short, intense efforts. Supplementing raises muscle phosphocreatine stores, improving the capacity for high-intensity work — more reps, more power, more total training stimulus, which over time means **more strength and muscle.**

Benefits (Strong evidence): increased **strength, power, and lean mass** with resistance training; improved high-intensity exercise capacity and recovery between efforts. **Emerging benefits: cognitive function** (especially under stress or sleep deprivation — Chapter 28), and possible support for **bone, mood, and healthy aging** (creatine is increasingly studied as a longevity-relevant supplement, particularly for older adults fighting sarcopenia).

Dosing. 3–5 g per day, every day, taken at any time (timing doesn't matter much; consistency does). An optional **loading phase** (~20 g/day split into 4 doses for 5–7 days) saturates muscle stores faster, after which 3–5 g/day maintains them — but loading isn't necessary; daily 3–5 g reaches saturation in ~3–4 weeks.

Form. Monohydrate is the cheapest, most-studied, and best form — fancier, pricier forms (HCl, buffered, etc.) offer **no proven advantage.** Don't pay extra.

Safety and myths. Creatine is **safe for long-term use in healthy people.** Key myths debunked: it does **not** harm the kidneys (it raises serum creatinine, a *marker*, not damage — Chapter 20 — so tell your doctor you take it); it does **not** cause dangerous dehydration or cramping (evidence shows the opposite if anything); the modest initial weight gain is **water drawn into muscle**, not fat. A small minority are "non-responders" (already high muscle creatine). Creatine is the rare supplement that is both **highly effective and genuinely cheap and safe.**

◆

26.2 Protein powder (whey and casein)

What it is. Protein powder is simply a **convenient, concentrated food source of protein** — most commonly **whey** and **casein** (both from milk), plus plant options (soy, pea, blends).

Chapter 27 — Performance Tier

▣ Active Summary


The core idea. A handful of supplements have **strong evidence for acutely improving training and athletic performance.** Unlike the foundational tier (broad health benefits), these are **targeted ergogenic aids** — they help you train harder or perform better, which indirectly supports your results.

- **Caffeine — STRONG. ~3–6 mg/kg**, ~30–60 min pre-training. The most reliable legal ergogenic: improves strength, power, endurance, focus, and reduces perceived effort. Tolerance builds; avoid late-day dosing (sleep — Chapter 10).
- **L-Citrulline (or citrulline malate) — MODERATE. ~6–8 g** pre-workout; raises nitric oxide and blood flow ("pump"), may improve reps and reduce soreness. Better absorbed than arginine.
- **Beta-alanine — STRONG (for 1–4 min efforts). ~3.2–6.4 g/day** (split to limit tingling); raises muscle carnosine to buffer acidity, improving high-intensity endurance. Requires **weeks of daily loading** — it's not an acute pre-workout.
- **Dietary nitrate (beetroot) — MODERATE. ~300–600 mg nitrate** (~500 mL beet juice) pre-endurance; improves oxygen efficiency and endurance.
- **Sodium bicarbonate — MODERATE. ~0.2–0.3 g/kg** pre high-intensity; buffers acidity; GI distress common.

Pre-workouts are mostly **caffeine + citrulline + beta-alanine (+ sometimes creatine)** — buy validated ingredients at effective doses and **ignore proprietary-blend "pixie dust."**

◆ Key Points

- **Caffeine (3–6 mg/kg):** the most reliable ergogenic — but mind tolerance and sleep.
- **Citrulline (6–8 g):** blood flow/pump, possible rep and soreness benefit.
- **Beta-alanine (3.2–6.4 g/day, chronic):** buffers acidity for 1–4 min efforts.
- **Nitrate/beetroot:** endurance/oxygen efficiency.
- **Build pre-workouts from proven ingredients at real doses** — skip proprietary blends.



The performance-tier supplements with real evidence (Grgic; Trexler). Schematic strength.

27.1 Caffeine — the most reliable ergogenic

What it is. A stimulant found in coffee, tea, and supplements — and the **single most reliably effective legal performance aid** in sports science.

How it works. Caffeine **blocks adenosine receptors** (reducing the perception of fatigue), increases alertness and central drive, and lowers **perceived exertion** — so a given effort feels easier and you can push harder. It benefits **strength, power, muscular endurance, aerobic endurance, reaction time, and focus** (Grgic[1] et al. meta-analyses).

Dosing and timing. ~3–6 mg/kg body weight, taken ~30–60 minutes before training (a 70 kg person → ~210–420 mg). Lower doses still help focus; higher doses raise side-effect risk without proportional benefit.

Tolerance and cautions. Tolerance builds with regular use, blunting the effect — periodically reducing intake or cycling restores sensitivity (though some performance benefit persists even in habitual users). Avoid dosing **within ~8–10 hours of bedtime** — caffeine has a long half-life and **wrecks sleep** (Chapter 10), which would undo far more than it gives. Side effects at higher doses include jitteriness, anxiety, raised heart rate, and GI upset; sensitive individuals and those with certain cardiac conditions should be cautious. Pairing caffeine with **L-theanine** smooths the jitter (Chapter 29).

◆

27.2 L-Citrulline

What it is. An amino acid that the body converts to **arginine**, boosting **nitric oxide (NO)** production — which dilates blood vessels and increases blood flow.

How it works and benefits (Moderate). By raising NO and blood flow, citrulline enhances the **"pump,"** may **increase training volume (reps)**, improve **blood flow and nutrient delivery**, and **reduce muscle soreness.** It's **better absorbed than supplemental arginine** (which is largely broken down before reaching circulation), making citrulline the more effective NO precursor. Evidence is moderate — real but smaller and less consistent than caffeine or creatine.

Chapter 28 — Longevity & Metabolic Tier


▣ Active Summary

The core idea. This tier covers supplements taken for **metabolic health and longevity** rather than acute performance. The honest reality (per Chapter 25) is that this category is **heavy on hype and light on proven human longevity outcomes** — several are mechanistically interesting and a few are genuinely useful for specific purposes, but **none has been shown to extend human lifespan.**

- **Berberine — MODERATE. ~500 mg ×2–3/day** with meals; meaningfully lowers blood glucose and lipids (effect approaching some glucose-lowering drugs). GI side effects and **real drug interactions** — treat it like a botanical drug, not a casual supplement.
- **L-Carnitine — MODERATE (specific uses). ~2 g/day**; roles in fat metabolism and possibly recovery and fertility; **not an effective stand-alone fat burner** in most healthy people.
- **Glutathione & NAC — EMERGING/WEAK for "anti-aging"; NAC better evidenced.** Oral glutathione is poorly absorbed; **NAC raises glutathione more reliably.** IV/IM glutathione (aesthetic "skin whitening") is **off-label with limited rigorous evidence** (Chapter 24).
- **NAD^+ precursors[2] (NR, NMN) — EMERGING.** Reliably **raise NAD^+ in humans**, but **no proven human healthspan/lifespan benefit** — promising, not proven.
- **CoQ10 — MODERATE (specific). ~100–200 mg/day**; useful for **statin-associated muscle symptoms** and certain conditions; general benefit modest.

◆ Key Points

- **Berberine:** genuine glucose/lipid lowering — but GI effects and drug interactions.
- **L-Carnitine:** specific metabolic/recovery roles; **not a fat-loss pill.**
- **NAC > oral glutathione** for raising glutathione; IV glutathione is off-label cosmetic.
- **NAD^+ precursors raise NAD^+ but have no proven longevity outcome** in humans.
- **CoQ10:** mainly for statin muscle symptoms and specific conditions.
- **No supplement here is proven to extend human lifespan.**



The longevity/metabolic tier: mechanistically interesting, but none proven to extend human lifespan.

28.1 Berberine

What it is. A compound extracted from several plants (e.g., barberry, goldenseal), traditionally used and now studied as a **metabolic** supplement.

How it works and benefits (Moderate). Berberine **activates AMPK** — the pro-maintenance, pro-longevity energy sensor (Chapter 1) — and meta-analyses show it **meaningfully lowers fasting glucose, HbA1c, LDL/triglycerides, and supports insulin sensitivity**, with effect sizes **approaching metformin** in some studies. This has earned it the nickname "nature's metformin," and it's a genuine metabolic tool.

Cautions. Treat berberine[1] more like a **botanical drug** than a casual supplement: it has **poor bioavailability**, commonly causes **GI side effects** (cramping, diarrhoea, constipation), and — importantly — has **real drug interactions** (it inhibits CYP enzymes, affecting how other medications are metabolised) and should not be combined casually with prescription drugs or in pregnancy. **Dosing** is typically **~500 mg, 2–3 times daily, with meals** (dihydroberberine is a more bioavailable form). Useful for metabolic support, but not a no-thought supplement.

◆

28.2 L-Carnitine

What it is. A compound central to **fat metabolism** — it shuttles fatty acids into mitochondria to be burned for energy.

Benefits (Moderate, specific). Because of its role in fat oxidation, L-carnitine is heavily **marketed as a fat burner** — but in most healthy people with adequate carnitine, **supplementing does not meaningfully increase fat loss** (it's not the rate-limiting step). Its more legitimate, if modest, uses: possible benefits for **exercise recovery and reduced muscle damage**, **male fertility** (sperm quality), and specific clinical **carnitine-deficiency** states. Some forms (acetyl-L-carnitine) are studied for cognitive/neurological purposes with mixed evidence.

Chapter 29 — Recovery, Energy, Brain & Sleep


▣ Active Summary

The core idea. This tier covers supplements taken for **recovery, sleep, stress, cognition, and energy** — areas flooded with products, most of which do little. A few have **genuine, if modest, evidence**; the rest are marketing. And the recurring principle holds: **sleep, nutrition, and training drive recovery far more than any pill.**

- **Recovery / anti-soreness: tart cherry** (MODERATE — soreness and sleep), omega-3 (mild), adequate protein and carbohydrate. **Critically, avoid high-dose antioxidant vitamins C/E around training** — they can **blunt the adaptive response** (Paulsen[1] 2014), echoing the cold-water-immersion caution (Chapter 10).
- **Sleep: glycine ~3 g** (MODERATE — sleep quality), **magnesium** (mild — Chapter 26), **L-theanine** (calming); **melatonin (0.5–3 mg)** is a **circadian/timing tool, not a sedative** — low doses, used correctly, shift the clock.
- **Stress / adaptogens: ashwagandha** (MODERATE — ~300–600 mg/day standardised extract may reduce stress/cortisol and modestly aid sleep and possibly strength).
- **Nootropics: caffeine + L-theanine** (best-evidenced everyday stack), **creatine** (cognitive, esp. sleep-deprived — Chapter 26), **omega-3**; most exotic nootropics are **weak/marketing.**
- **Energy:** caffeine works; **B-vitamin "energy" supplements help only if you're deficient** — otherwise they do nothing.

◆ Key Points

- **Tart cherry** (soreness/sleep) and **glycine** (sleep quality) are the better-evidenced niche picks.
- **Don't megadose vitamins C/E around training** — blunts adaptation.
- **Melatonin is a circadian tool, not a sleeping pill** — use low doses to shift timing.
- **Caffeine + L-theanine** is the best everyday nootropic stack; **creatine** aids cognition too.
- **Ashwagandha** has moderate evidence for stress/cortisol.
- **Sleep, food, and training beat every recovery supplement.**



The recovery/sleep supplements with real (if modest) evidence — most of the category is marketing.

29.1 Recovery and anti-soreness

Most "recovery" supplements add little beyond what food and sleep already do (Chapter 10). The exceptions with real signal:

- **Tart cherry (Montmorency):** the best-evidenced recovery supplement here — **reduces muscle soreness and markers of damage** after hard exercise, and (via its natural melatonin and polyphenol content) may **improve sleep.** Useful around heavy training blocks or competition. Dose: ~480 mg extract or ~250–350 mL juice.
- **Omega-3** (Chapter 26): mild anti-inflammatory support for recovery.
- **Adequate protein and carbohydrate**: the real recovery foundation — protein for repair, carbohydrate to refill glycogen.

The antioxidant caveat — important. It's tempting to take **high-dose antioxidant vitamins (C and E)** to "reduce exercise-induced oxidative stress and soreness." **Don't make this a routine around training.** The exercise-induced oxidative and inflammatory signal is **part of how you adapt** — blunting it with high-dose antioxidants can **impair the training adaptations** you're working for (Paulsen et al. 2014 showed high-dose C/E supplementation blunted some adaptations to training). This parallels the cold-water-immersion caution (Chapter 10): **don't suppress the very signals that drive adaptation.** Get antioxidants from a **whole-food diet** (which doesn't cause this problem) rather than megadosed isolated vitamins around workouts.

◆

29.2 Sleep supplements

Sleep quality is best protected by **behaviour and environment** (Chapter 10); supplements are secondary. The ones with reasonable evidence:

- **Glycine (~3 g before bed):** moderate evidence for **improving subjective sleep quality** and reducing time to fall asleep, possibly via mild body-temperature lowering. Low-risk, inexpensive.
- **Magnesium** (Chapter 26): mild benefit for sleep and relaxation, especially if intake is low; glycinate form in the evening.
- **L-theanine (~100–200 mg):** promotes calm/relaxation without sedation; can ease pre-sleep mental activation and pairs well with reducing evening stimulation.

◆

Chapter 30 — Fat Burners & "Shred" Stacks

▣ Active Summary

The core idea. "Fat burner" supplements are among the **most marketed and least effective** category in the entire industry. The single most important fact: **no supplement meaningfully burns fat without an energy deficit** (Chapter 11). Fat loss is driven by the **deficit, protein, training, daily movement (NEAT/steps), and sleep** — the "fat burner" is, at best, a small accelerant and, at worst, useless or dangerous.

What has *some* (small) evidence: caffeine (modest metabolic and appetite effect, blunted by tolerance), **green-tea catechins (EGCG) + caffeine** (small), **yohimbine** (may target stubborn fat in a fasted state, but causes anxiety/blood-pressure effects), and — the real levers — **protein and fibre** (satiety, which drives adherence to the deficit).

What doesn't work: L-carnitine alone (Chapter 28), **raspberry ketones, garcinia cambogia, CLA, forskolin, and "metabolism boosters"** — weak or null human evidence.


What's dangerous (avoid entirely): DNP[2] (2,4-dinitrophenol — causes fatal hyperthermia, has killed users), **clenbuterol** (Chapter 38), **ephedra/unregulated stimulant blends**, and contaminated "research chemical" fat burners.

The honest reality: the "shred stack" that works is the **deficit + protein + training + steps + sleep.** The supplement is mostly **expensive caffeine.**

◆ Key Points

- **No supplement burns fat without a deficit** — that's the whole game.
- **Caffeine** is the only "fat burner" ingredient with real (small) effect; tolerance blunts it.
- **Protein and fibre** are the genuinely useful "fat-loss supplements" — via satiety.
- **Most fat burners (carnitine, raspberry ketone, garcinia, CLA, forskolin) don't work.**
- **DNP is potentially lethal; clenbuterol and unregulated stimulants are dangerous — avoid.**

◆



What really drives fat loss — the 'fat burner' is at best a small accelerant on top of this.

30.1 The core truth

Before any ingredient discussion, internalise the principle: **fat loss requires a sustained energy deficit (Chapter 11), and no pill suspends that.** Every legitimate mechanism a "fat burner" could use — slightly raising metabolic rate, modestly suppressing appetite, marginally increasing fat oxidation — produces effects that are **small** and that **only matter within the context of a deficit you're already running.** A fat burner taken without a deficit does nothing to your body fat. This is why the entire category is built on a misleading promise: it sells the *feeling* of doing something (often just stimulant effects) while the actual fat loss comes from the diet and activity the person is doing anyway. **The most effective "fat-loss supplements" are protein and fibre** — not because they "burn fat," but because they increase **satiety**, making the deficit easier to sustain.

◆

30.2 What has some (small) evidence

A few ingredients have **modest, real** effects — worth knowing, but keep expectations low:

- **Caffeine** (Chapter 27) — slightly raises metabolic rate (thermogenesis) and can **modestly suppress appetite** and improve training output. The effect is **small and blunted by tolerance**, but caffeine is the one "fat burner" ingredient with genuine (if minor) support — and most commercial fat burners are essentially **caffeine plus filler.**
- **Green-tea catechins (EGCG) + caffeine** — a small synergistic effect on fat oxidation/metabolic rate; real but minor.
- **Yohimbine** — an alpha-2 antagonist that can **mobilise catecholamine-resistant ("stubborn") fat**, with the best evidence in a **fasted state**. The catch: it commonly causes **anxiety, palpitations, raised blood pressure, and jitteriness**, especially in sensitive people, and interacts with some conditions/medications — so it's a niche tool with a real side-effect profile, not a casual addition.

Chapter 31 — IV Therapies & Injectable Wellness


▣ Active Summary

The core idea. Intravenous (IV) vitamin drips, **NAD⁺ infusions**, IV/IM **glutathione**, and vitamin injections are a fast-growing "wellness" and aesthetic category — heavily marketed, **mostly under-evidenced**, and meaningfully beneficial only in a narrower set of situations than the marketing implies. The honest rule mirrors all of Part V: **IV/injectable nutrients reliably help when correcting a genuine deficiency or malabsorption; for healthy, replete people they mostly produce expensive urine and a placebo glow.**

- **IV vitamin drips (e.g., "Myers' cocktail"):** little rigorous evidence of benefit in healthy people [1][2]; the appeal is largely **hydration + placebo + rapid repletion** in the genuinely deficient.
- **IV NAD⁺:** raises NAD⁺ and is popular for "anti-aging/energy," but **human outcome evidence is minimal**, infusions are **slow, costly, and cause flushing/nausea/chest discomfort if run fast** [3]; promising biology, unproven benefit (Chapter 32).
- **IV/IM glutathione (skin-lightening): limited high-quality evidence**, transient effect, off-label, with sterility/safety considerations [4][5] — directly relevant to aesthetic practice.
- **Vitamin injections (B12, vitamin D, iron): genuinely indicated** for documented deficiency or malabsorption (e.g., B12 in pernicious anaemia, IV iron in iron-deficiency intolerant of oral) — real medicine, not wellness fluff.
- **Safety & regulation:** IV/injectables carry **infection, sterility, fluid/electrolyte, and contamination risks**; in India, several injectables sit in a **CDSCO grey zone** and must be used within proper regulatory and sterility standards.

◆ Key Points

- **IV nutrients help mainly to correct deficiency/malabsorption** — not as routine wellness in replete people.
- **Myers' cocktail and "energy drips": weak evidence**; mostly hydration + placebo.
- **IV NAD⁺: biology promising, human outcomes unproven; infusion side effects real.**
- **IV/IM glutathione for skin: limited, transient evidence; off-label.**
- **B12 / iron / vitamin D injections: legitimate for documented deficiency.**
- **Injectables carry real infection, sterility, and regulatory considerations.**



Routes of drug administration — enteral (oral, sublingual, rectal), parenteral (IV, IM, subcutaneous), inhaled, and topical/transdermal.

31.1 What "IV and injectable wellness" is

Beyond oral supplements lies a parallel market delivering nutrients **directly into the bloodstream or muscle** — IV "drips" in wellness lounges and clinics, and intramuscular (IM) injections of vitamins. The marketing pitch is **bioavailability and immediacy**: by bypassing the gut, IV nutrients reach the blood at 100% availability, supposedly producing faster, stronger effects than pills. There is a kernel of truth — IV bypasses absorption limits — but the pitch obscures the central fact: **for most nutrients in a healthy, well-fed person, the body is already replete, and flooding the blood with more simply increases urinary excretion** (for water-soluble vitamins) without added benefit. The legitimate niche is **genuine deficiency, malabsorption, or inability to take oral** — where parenteral delivery is real, effective medicine. Distinguishing the two is the whole game.

31.2 IV vitamin drips ("Myers' cocktail" and friends)

The archetype is the **"Myers' cocktail"** — an IV mix of vitamin C, B vitamins, magnesium, and calcium, marketed for fatigue, immunity, migraines, "wellness," and recovery. Despite decades of popularity, **rigorous evidence of benefit in healthy or even symptomatic people is weak** [1][2]: the few controlled trials (e.g., in fibromyalgia) have generally **failed to show benefit over placebo**, and much of the perceived effect is attributable to **rehydration, rest, and expectation.** For a healthy person eating adequately, an IV multivitamin offers **no demonstrated advantage over a balanced diet** and the relevant oral supplements. The drips are not usually *harmful* in competent hands, but they are an **expensive, low-evidence** indulgence — the clearest example of the Chapter 25 principle that bypassing the gut doesn't create benefit where no deficiency exists. (And note:

◆

Chapter 32 — NAD⁺, NMN, NR, Multivitamins & Micronutrients

▣ Active Summary


The core idea. This chapter covers the **"foundational insurance" and "longevity-molecule" supplements** taken by huge numbers of people: **NAD⁺ precursors (NR, NMN), multivitamins, and individual micronutrients.** The evidence splits cleanly: **NAD⁺ precursors reliably raise a biomarker but have no proven human longevity outcome**, while **multivitamins/micronutrients clearly help when correcting a deficiency** and show **modest, selective benefits otherwise.**

- **NR & NMN (NAD⁺ precursors):** oral NR (~250–1000 mg/day) and NMN (~250–600 mg/day) **reliably raise blood NAD⁺** and are well-tolerated [1][2]; NMN improved muscle insulin sensitivity in one trial [3], NR modestly lowered blood pressure [1], but **other trials show no metabolic effect** [4], and **no trial shows extended healthspan/lifespan** — the surrogate-marker trap (Chapter 25).
- **Multivitamins:** in large RCTs, a daily multivitamin produced a **modest ~8% reduction in total cancer** (PHS-II) [5] and **improved cognition/memory in older adults** (COSMOS) [6][7], but **no clear cardiovascular or mortality benefit**, and the **USPSTF (2022) found insufficient evidence** to recommend them for disease prevention in the general, well-nourished population [8].
- **Individual micronutrients** (B12, folate, iron, vitamin D, iodine, zinc, selenium) matter most for **correcting specific deficiencies and life-stage needs** (e.g., folate in pregnancy).
- **The frame:** food first; multivitamins as **cheap insurance** for gaps; **avoid megadosing** isolated nutrients (some cause harm).

◆ Key Points

- **NR/NMN raise NAD⁺ reliably; no proven human longevity outcome** (watch the science).
- **Multivitamins: modest cancer ↓ (PHS-II) and cognition ↑ (COSMOS); no CVD/mortality benefit; USPSTF "insufficient evidence."**
- **Micronutrients shine at correcting deficiency** and life-stage needs (folate in pregnancy).
- **Food first; multivitamin as inexpensive insurance** for gaps.
- **Don't megadose** isolated nutrients — some (beta-carotene, vitamin E) showed *harm*.
- **Combine smartly:** iron + vitamin C, fat-soluble vitamins with a fatty meal, vitamin D + magnesium/K2; **separate** iron from calcium and balance zinc with copper (§32.7).

◆



The structure of NAD⁺ — nicotinamide and adenine joined by two riboses and a diphosphate bridge. The coenzyme that powers energy metabolism, sirtuins, and DNA repair.

32.1 NAD⁺ — the biology in brief

NAD⁺ (nicotinamide adenine dinucleotide) is a coenzyme essential for **energy metabolism** and a required substrate for the **sirtuins** (longevity-associated enzymes — Chapter 1). NAD⁺ levels **decline with age**, which is the entire rationale behind supplementing its precursors to "restore youthful NAD⁺." The two leading oral precursors are **nicotinamide riboside (NR)** and **nicotinamide mononucleotide (NMN)** — both forms of vitamin B3 chemistry that the body converts to NAD⁺.

32.2 NR and NMN — what the human trials actually show

The crucial distinction is between **raising NAD⁺ (established)** and **improving health outcomes (not established):**

- **NR raises NAD⁺ and is safe:** the landmark trial by **Martens et al. (*Nature Communications* 2018)** showed NR (500 mg twice daily, 6 weeks) **reliably increased blood NAD⁺ in healthy middle-aged/older adults, was well-tolerated even at 1000 mg/day**, and produced a **modest reduction in systolic blood pressure** (≈ −4 mmHg overall; larger in those with elevated blood pressure) [1].
- **NMN raised muscle insulin sensitivity in one trial: Yoshino et al. (*Science* 2021)** found 10 weeks of NMN (250 mg/day) increased **clamp-measured muscle insulin sensitivity by ~25%** in prediabetic women [3] — a genuinely interesting metabolic signal.
- **But the results are inconsistent:** several well-controlled NR trials (e.g., **Remie et al. 2020**) found **no change** in insulin sensitivity, body composition, or hepatic fat despite confirmed NAD⁺ engagement [4]; vascular and metabolic signals across trials are **mixed** [2].
- **And — critically — no human trial has shown extended healthspan or lifespan**, or hard clinical-outcome benefit, from raising NAD⁺ with NR or NMN. The longevity case remains **mechanistic and animal-based** (where it is itself mixed).

This is the textbook **surrogate-marker trap** (Chapter 25): NR/NMN change a biomarker (NAD⁺) reliably, but **changing the biomarker is not the same as changing an outcome you care about.**

Chapter 33 — Supplement Dosing Reference Tables

▣ Active Summary

The core idea. This chapter consolidates **everything from Part V into one-stop lookup tables** — doses, timing, evidence tiers, and key notes — plus **sensible starting stacks by goal.** Use it as the quick-reference you return to; the preceding chapters explain the *why* behind each entry.

The honest framing (restated): supplements are the **last ~5%** (Chapter 25). The tables below are organised by tier so you can see at a glance which few are **Strong** (worth it for most), which are **Moderate/situational**, and which to **skip.** Buy **third-party tested** products (NSF Certified for Sport, Informed Sport), dose at the **studied amounts** (not proprietary-blend sprinkles), and remember that **food, training, sleep, and body composition do the real work.**

◆ Key Points

- **Strong tier for most people:** creatine, protein, caffeine, omega-3, (vitamin D if deficient).
- **Dose at studied amounts; buy third-party tested.**
- **Skip:** raspberry ketone, garcinia, CLA, forskolin, "detox," exotic nootropics, resveratrol.
- **Avoid (dangerous):** DNP, clenbuterol, ephedra, unregulated stimulant blends.
- **Stacks should match your goal** — don't take everything.

33.1 How to use these tables

Each entry lists the **evidence tier** (Chapter 25), a **practical dose**, **timing**, and a **key note**. A few rules: - **Doses are for healthy adults** and are general references, **not medical advice** — adjust for your context and check interactions, especially if on medication or with health conditions. - **Tier reflects the *specific* use listed** — the same supplement can be Strong for one purpose and Weak for another. - **More is not better** — these are effective doses, not minimums to exceed. - **Consistency matters** for the daily ones (creatine, beta-alanine, omega-3, vitamin D).

33.2 Foundational tier (broad benefit — Chapter 26)

Supplement	Tier	Dose	Timing	Note
Creatine monohydrate	Strong	3–5 g/day	Any time, daily	Most proven; safe long-term; monohydrate only
Whey protein	Strong (tool)	20–40 g	Around training	Fast, high-leucine
Casein	Strong (tool)	20–40 g	Pre-sleep	Slow protein, overnight MPS
Omega-3 (EPA+DHA)	Mod/Strong	1–3 g/day combined	With food	Check EPA+DHA content; low-oxidation oil
Vitamin D3	Moderate	1000–2000 IU/day	With fat	Correct deficiency; target 25-OH-D 30–50 ng/mL
Magnesium (glycinate)	Moderate	200–400 mg/day	Evening	Sleep, muscle, glucose

33.3 Performance tier (Chapter 27)

Supplement	Tier	Dose	Timing	Note
Caffeine	Strong	3–6 mg/kg	30–60 min pre	Tolerance builds; not late in day
L-Citrulline	Moderate	6–8 g	30–60 min pre	Blood flow/pump
Beta-alanine	Strong (1–4 min efforts)	3.2–6.4 g/day	Daily, chronic	Loads over weeks; tingling benign
Dietary nitrate (beetroot)	Moderate	300–600 mg nitrate	2–3 h pre	Endurance/economy
Sodium bicarbonate	Moderate	0.2–0.3 g/kg	60–90 min pre	GI distress; trial first

PART VI — PERFORMANCE PHARMACOLOGY (CLINICAL / EDUCATIONAL)

Scope note for Part VI. This Part covers the **pharmacology, clinical context, duration of use, and — critically — the risk/harm profile** of hormones and performance-enhancing drugs, at the level a clinician or well-informed reader needs to understand and counsel on them. It deliberately does **not** provide performance dosing, cycling, or stacking protocols, because those constitute operational guidance for illicit, health-damaging non-medical use. **Legitimate, monitored clinical hormone therapy** is described in general terms; individual prescribing belongs in a clinical relationship. The purpose throughout is **education and harm-awareness**, not enablement.

Chapter 34 — Hormone Therapy: TRT & HRT Pharmacology

▣ Active Summary

The core idea. This chapter covers the **pharmacology of clinical hormone therapy** — how testosterone and oestrogen/progesterone formulations work, how they're used, for how long, and their benefits and harms. It builds on the clinical overview in Chapter 23 with more pharmacological detail, while keeping the same boundary: **education, not a self-prescription protocol.**

Testosterone formulations differ mainly by **ester (which controls release rate) and route**: long-acting **injectable esters** (enanthate, cypionate, undecanoate), short-acting (propionate), **transdermal** gels/patches, **oral** testosterone undecanoate (newer formulations avoiding the liver toxicity of older orals), and **pellets.** The choice affects stability of levels, dosing frequency, and side-effect profile.


Clinical TRT aims to **restore physiological levels** in diagnosed hypogonadism — *not* supraphysiological enhancement — and is a **long-term, monitored** therapy.

Female HRT uses **oestradiol** (transdermal preferred for a better safety profile) plus **progesterone** (if the uterus is present), individualised, with the timing hypothesis (Chapter 23) governing benefit/risk.

Key safety axes across hormone therapy: **erythrocytosis, fertility suppression, oestradiol balance, prostate (men), clotting/breast (women), and cardiovascular monitoring.**

◆ Key Points

- **Esters control release rate**; route (injectable/transdermal/oral/pellet) shapes stability and side effects.
- **Clinical TRT = physiological restoration**, long-term and monitored — not enhancement.
- **Modern oral testosterone undecanoate avoids** the liver toxicity of old oral testosterones.
- **Female HRT:** transdermal oestradiol + progesterone (if uterus), individualised.
- **Monitor:** haematocrit, fertility, oestradiol, prostate (men); clotting/breast (women); cardiovascular.



The clinical pathway for testosterone therapy — diagnosis, reversible causes, and monitoring (Bhasin, Endocrine Society).

34.1 The clinical frame

Hormone therapy means **restoring deficient hormones to physiological levels** for a diagnosed clinical need — male hypogonadism, female menopausal symptoms (Chapter 23). This is fundamentally different from the **supraphysiological** hormone use of anabolic steroids for performance (Chapter 35): clinical therapy aims for **normal**, monitored levels and treats a deficiency; performance use aims for **far-above-normal** levels and accepts substantial risk for enhancement. This chapter is about the **clinical pharmacology** — understanding the drugs themselves — and applies the same educational, non-prescriptive boundary as the rest of Part VI.

◆

34.2 Testosterone formulations — esters and routes

The pharmacology of testosterone therapy centres on **getting testosterone into the body in a stable, physiological way.** Pure testosterone is cleared too fast to be practical, so it's modified or delivered in ways that control release.

Esters (for injectables). An **ester** is a fatty-acid chain attached to the testosterone molecule. Once injected into a muscle or fat depot, the ester slows the hormone's release into circulation — **longer ester chains = slower release = less frequent dosing and steadier levels:** - **Testosterone enanthate / cypionate** — **long-acting** esters; the most common injectable TRT, dosed roughly weekly (or split), giving relatively stable levels. - **Testosterone undecanoate (injectable)** — a **very long-acting** ester allowing dosing every several weeks. - **Testosterone propionate** — **short-acting**; faster on/off, requiring frequent injections; less used clinically.

The ester only changes the *kinetics* (release rate), not the hormone itself — once the ester is cleaved in the body, it's identical testosterone.

Routes: - **Injectable** (esters, as above) — effective and economical; the trade-off is **peaks and troughs** between injections (more pronounced with longer intervals), which more frequent dosing smooths. - **Transdermal (gels, patches)** — applied daily to skin, giving **steady, physiological daily levels** that mimic natural rhythms; downside is the **risk of transfer** to others by skin contact and variable absorption. - **Oral testosterone undecanoate** — newer oral formulations are absorbed via the lymphatic system, **avoiding the first-pass liver toxicity** that made older oral testosterones (17α-alkylated) hepatotoxic (Chapter 35); a convenient option without the injection. - **Pellets** — implanted under the skin, releasing testosterone over months; convenient but requires a minor procedure and is harder to adjust.

The clinical goal across all routes is **stable, physiological restoration** with minimal peaks/troughs and manageable side effects.

◆

34.3 How clinical TRT is used, and for how long

In diagnosed hypogonadism (Chapter 23 — symptoms plus repeated low morning testosterone, reversible causes addressed), TRT restores testosterone to the **normal physiological range**, with the dose titrated to **symptoms and lab levels** (aiming for mid-normal, not supraphysiological). It is generally a **long-term, often indefinite** therapy, because the underlying deficiency persists — and because **stopping after long use leaves the natural axis suppressed** (the HPG axis was downregulated by the exogenous testosterone — Chapter 23), often requiring a

Chapter 35 — Anabolic-Androgenic Steroids: Pharmacology & Harm Profile

▣ Active Summary

Scope reminder. This chapter explains **what anabolic-androgenic steroids (AAS) are, how they work, and — most importantly — the full picture of their harms**, at the level a clinician or informed reader needs to understand and counsel on them. It does **not** provide performance dosing, cycling, or stacking protocols. The purpose is **education and harm-awareness.**


What they are. AAS are **synthetic derivatives of testosterone** that bind the **androgen receptor** to increase muscle protein synthesis and satellite-cell activity. They are grouped by base structure: **testosterone derivatives, DHT (dihydrotestosterone) derivatives, and 19-nortestosterone (nandrolone) derivatives**, with many delivered as **oral 17α-alkylated** compounds.

They work — but at a cost. Supraphysiological androgen doses **reliably build muscle and strength, even without training** (Bhasin[1] et al., *NEJM* 1996) — which is precisely why the harms matter, because the doses used far exceed physiological replacement.

The harm profile is broad and well-documented (Pope et al., Endocrine Society scientific statement 2014): - **Cardiovascular:** adverse lipids (low HDL, high LDL/ApoB), hypertension, left-ventricular hypertrophy/ cardiomyopathy, premature atherosclerosis, thrombosis. - **Endocrine:** HPG-axis shutdown, infertility, testicular atrophy, gynecomastia, dependence. - **Hepatic:** especially **oral 17α-alkylated** agents (cholestasis, tumours, peliosis). - **Psychiatric:** aggression, hypomania, depression on withdrawal, **dependence.** - **Other:** acne, male-pattern hair loss, polycythemia, tendon injury risk; plus **unregulated-sourcing** risks (contamination, mislabeling, dosing errors).

◆ Key Points

- **AAS = testosterone derivatives acting on the androgen receptor** to drive muscle growth.
- **They work at supraphysiological doses** — which is why the harms are serious.
- **Harms span cardiovascular, endocrine, hepatic, psychiatric, and more.**
- **HPG shutdown** can cause prolonged/permanent hypogonadism and infertility.
- **Oral 17α-alkylated agents are specifically hepatotoxic.**
- **Dependence is real and under-recognised**; black-market sourcing adds risk.



The landmark Bhasin (NEJM 1996) trial: supraphysiologic testosterone raised fat-free mass even without exercise — reported, not a protocol.

35.1 What AAS are and how they work

Anabolic-androgenic steroids are **synthetic modifications of testosterone**, engineered to alter the balance of **anabolic** (tissue-building) versus **androgenic** (masculinising) effects, or to change metabolism (oral availability, resistance to aromatisation). They work by **binding the androgen receptor** in muscle and other tissues, which **increases muscle protein synthesis, activates satellite cells (adding myonuclei — Chapter 4), and reduces protein breakdown** — producing muscle growth and strength gains beyond anything achievable naturally. The "**anabolic:androgenic ratio**" marketing of different compounds (claiming more muscle-building with less masculinising effect) is somewhat artificial — all AAS are androgens and carry androgenic effects to varying degrees, and the ratio doesn't eliminate the systemic harms.

◆

35.2 They work — which is exactly why the harms matter

It's important to be honest: **AAS are effective.** The landmark study by **Bhasin et al. (*NEJM* 1996)** showed that supraphysiological testosterone **built significant muscle and strength even in men who did not train**, and far more in those who did — dose-dependently. This efficacy is not in dispute. But it's the very reason the harm profile is so significant: the doses required for these physique/performance effects are **many times physiological replacement** (Chapter 34), and at those supraphysiological levels the body experiences a cascade of adverse effects across multiple organ systems. **Effectiveness and danger are linked** — the same supraphysiological androgen exposure that builds the muscle drives the harms.

◆

35.3 The compound classes (educational taxonomy)

AAS are categorised by their chemical base. This is **educational taxonomy** — what the classes *are* and their notable pharmacological properties — not a usage guide:

Chapter 36 — Ancillaries: Aromatase Inhibitors & SERMs

▣ Active Summary

The core idea. "Ancillaries" are drugs used to **manage oestrogen and the HPG axis** — they have **legitimate clinical indications** and are also misused alongside AAS. This chapter explains what they are, how they work, where they're genuinely indicated, and the crucial teaching point that **oestrogen is essential — over-suppressing it causes real harm.** *(Educational pharmacology, not a protocol.)*

Aromatase inhibitors (AIs) — anastrozole, letrozole, exemestane — **block the conversion of androgens to oestrogen. Legitimate use:** breast cancer and certain endocrine conditions. Misused to control oestrogen alongside AAS, where **crashing oestradiol harms lipids, bone, joints, libido, and mood.**


SERMs (selective oestrogen receptor modulators) — tamoxifen, raloxifene, clomiphene/enclomiphene — **modulate oestrogen receptors tissue-selectively** (blocking in some tissues, activating in others). **Legitimate uses:** breast cancer (tamoxifen, raloxifene), and **clomiphene/enclomiphene to stimulate the body's own testosterone** by raising LH/FSH (used in some male hypogonadism/fertility contexts, preserving the axis — unlike exogenous testosterone which suppresses it).

The key teaching point: oestrogen is not a "bad" hormone in men — it's essential for **bone, lipids, libido, joints, and cardiovascular health.** Excessively suppressing it (a common error in non-medical AAS use) is harmful.

hCG is another ancillary that **stimulates the testes directly**, used clinically to maintain testicular function/ fertility.

◆ Key Points

- **AIs block androgen→oestrogen conversion**; legit use is breast cancer/endocrine conditions.
- **SERMs modulate oestrogen receptors tissue-selectively**; clomiphene/enclomiphene **raise endogenous testosterone.**
- **Oestrogen is essential — crashing it harms bone, lipids, libido, joints, mood.**
- **Clomiphene preserves the HPG axis** (vs exogenous testosterone, which suppresses it).
- These are **real drugs with real indications**, not casual supplements.



How ancillaries work: aromatase inhibitors cut estrogen production; SERMs block its receptor.

36.1 What ancillaries are and why they exist

In hormone pharmacology, "**ancillaries**" are drugs used to **manage the downstream and feedback effects of androgens** — chiefly **oestrogen levels** (since some testosterone/AAS aromatises to oestrogen) and the **HPG axis** (Chapter 23). They have **genuine, important clinical indications** (notably in oncology and fertility/endocrinology) and are separately **misused in the AAS context** to control side effects or restart the suppressed axis. This chapter covers the **legitimate pharmacology and indications**, and the important physiological lessons they illustrate — especially about the essential role of oestrogen.

◆

36.2 Aromatase inhibitors (AIs)

What they are. Aromatase inhibitors — anastrozole, letrozole, exemestane — block the enzyme **aromatase**, which converts androgens (like testosterone) into **oestrogen.** By blocking this conversion, AIs **lower oestrogen levels.**

Legitimate clinical use. AIs are important drugs in **oestrogen-receptor-positive breast cancer** (especially in postmenopausal women, where they reduce the oestrogen that drives tumour growth) and in certain other endocrine conditions. This is their proper, evidence-based role.

Misuse and its harms. In the non-medical AAS context, AIs are misused to **suppress the oestrogen that rises when aromatising AAS are taken** (to prevent gynecomastia, water retention). The critical problem: **over-suppressing oestrogen ("crashing" oestradiol) is harmful.** Because oestrogen is essential in men (32.4), crashing it causes **poor lipid profiles, bone loss, joint pain, low libido, erectile dysfunction, and depressed mood.** The misuse of AIs to drive oestrogen too low is a common and damaging error — illustrating that the goal is **balance, not elimination, of oestrogen.**

◆

36.3 SERMs (selective oestrogen receptor modulators)

What they are. SERMs — tamoxifen, raloxifene, clomiphene, enclomiphene — bind oestrogen receptors and act **selectively by tissue**: blocking oestrogen's effect in some tissues while activating it in others. This tissue-selective behaviour is what makes them useful for different purposes.

Legitimate clinical uses: - Tamoxifen and raloxifene — important in **breast cancer** treatment/prevention (blocking oestrogen in breast tissue); raloxifene is also used for **osteoporosis** (acting like oestrogen in bone). - **Clomiphene / enclomiphene** — these **block oestrogen receptors at the hypothalamus/pituitary**, which the brain interprets as "low oestrogen," prompting **increased GnRH → LH/FSH → increased natural testosterone**

◆

Chapter 37 — Frontier Compounds: Myostatin Inhibitors, SARMs, Peptides & Gene Therapy

▣ Active Summary

Scope reminder. This chapter covers the **science and honest status** of the "next-generation" muscle/performance compounds — what they are, the biology, and where the evidence actually stands. It is **educational**, not a usage guide, and the recurring conclusion is **"promising biology, unproven and frequently unsafe products."**

Myostatin inhibitors. Myostatin is a **negative regulator of muscle growth**; blocking it (via follistatin, anti-myostatin antibodies, or ACVR2 ligand traps) produces **dramatic muscle gains in animals.** But **human trials (for muscular dystrophy, sarcopenia) repeatedly showed increased muscle *size* without proportional gains in *strength/function*, and development has largely stalled** on efficacy and safety hurdles. Not an approved performance therapy.

SARMs (selective androgen receptor modulators). Designed for **tissue selectivity** (muscle/bone over prostate). **None are FDA-approved; all are investigational or illicit.** They are **not "side-effect-free"** — they **suppress the HPG axis, affect lipids and the liver**, and products sold as SARMs are **frequently mislabeled or contaminated** (often containing actual steroids or nothing).


Peptides (GH secretagogues, BPC-157, TB-500, etc.) are **mostly unapproved and under-studied in humans**, with safety and contamination concerns; legitimate peptide therapeutics exist, but the "research-peptide" market is largely **unregulated.**

Gene therapy / follistatin gene transfer is **experimental**, with serious safety and ethical issues — not a real-world option.

◆ Key Points

- **Myostatin inhibitors:** big muscle gains in animals; in humans, **size without strength**, development stalled.
- **SARMs:** not approved, **not side-effect-free** (HPG suppression, lipids, liver), often contaminated.
- **Peptides:** mostly unapproved/under-studied; grey-market purity and safety concerns.
- **Gene therapy:** experimental; serious safety/ethics issues.
- **Theme: promising biology, unproven and often unsafe products.**

◆



The frontier of muscle/longevity pharmacology, sorted by how established — and how risky — each class is.

37.1 Myostatin inhibitors

The biology. Myostatin is a protein that acts as a **brake on muscle growth** — a negative regulator that limits how much muscle the body builds. Animals (and rare humans) with **non-functional myostatin genes** are **dramatically, visibly more muscular** ("double-muscled" cattle, the famous hyper-muscular myostatin-knockout mice and a documented hyper-muscular child). This makes **blocking myostatin** an obvious target for building muscle, pursued through several approaches: **follistatin** (a natural myostatin antagonist), **anti-myostatin antibodies**, and **ACVR2 receptor ligand traps** (which mop up myostatin and related proteins).

The human reality. This is where the hype meets disappointment. Multiple **pharmaceutical programs** developed myostatin inhibitors for **muscular dystrophy, sarcopenia, and muscle-wasting conditions** — and the consistent finding in human trials was that they **increased muscle *size* but produced little or no proportional improvement in *strength or physical function*.** Bigger muscle that isn't proportionally stronger or more functional isn't the breakthrough hoped for, and combined with safety and efficacy hurdles, **most of these drug programs were discontinued or stalled.** So despite the spectacular animal biology, **myostatin inhibition has not delivered a usable muscle-building therapy in humans**, and none is approved for performance. It remains a fascinating but **unfulfilled** target — a cautionary example of impressive mechanisms not translating.

◆

37.2 SARMs (selective androgen receptor modulators)

The concept. SARMs were designed to **selectively activate the androgen receptor in muscle and bone** while having **less effect on other tissues** (like the prostate) — the goal being "the muscle benefits of steroids without the side effects." This is an appealing pharmacological idea.

The reality. The marketing claim that SARMs are **"anabolics without side effects" is false: - None are FDA-approved** for human use — they remain **investigational drugs or illicit products** sold in a legal grey zone (often labeled "research chemicals not for human consumption"). - They are **not side-effect-free**: SARMs **suppress the natural HPG axis** (causing the same testosterone suppression and recovery issues as AAS — Chapters 21, 33), **negatively affect lipids** (lowering HDL), and some carry **liver toxicity** signals. - **Contamination and mislabeling are rampant** (Chapter 25): independent testing of products sold as SARMs frequently finds they contain **actual anabolic steroids, different compounds, wrong doses, or nothing active at all** — so users often don't know what they're taking. - Long-term safety in humans is **largely unknown.**

The honest summary: SARMs are **unapproved, not free of the steroid-like harms they're marketed to avoid, and sold in a contaminated, unregulated market** — a combination of unproven benefit and real, partly-unknown risk.

Chapter 38 — Non-Steroidal Ergogenics: Clenbuterol & Others

▣ Active Summary

The core idea. Beyond anabolic steroids, several **non-steroidal drugs** are misused for fat loss, muscle preservation, or performance — and they carry **serious, sometimes fatal, risks.** This chapter explains what they are and **why they're dangerous**, not how to use them.


Clenbuterol is a **β2-agonist** (a bronchodilator/asthma and veterinary drug) misused for **fat loss and mild anti-catabolic effects. It is not a steroid.** Its harm profile: **tachycardia, palpitations, cardiac arrhythmia, cardiac hypertrophy/toxicity, tremor, anxiety, insomnia, electrolyte disturbance (hypokalaemia)**, and overdose risk — made worse by its **long half-life**, which makes toxicity persist. Deaths and hospitalisations are documented.

Other misused non-AAS agents (educational flags): - **DNP** — a metabolic uncoupler causing **fatal hyperthermia**; has killed users (Chapter 30). **No safe dose.** - **Thyroid hormone (T3/T4)** misuse — cardiac and bone harm, suppression of the natural thyroid axis. - **Insulin** misuse — **life-threatening hypoglycaemia.** - **Growth hormone (GH)** misuse — acromegalic changes, insulin resistance, organ/tissue overgrowth.

These are covered to explain why they're dangerous — each carries severe, sometimes fatal, risks in non-medical use.

◆ Key Points

- **Clenbuterol is a β2-agonist (not a steroid)** misused for fat loss; **cardiac toxicity, arrhythmia, long half-life.**
- **DNP can be lethal** (fatal hyperthermia) — no safe dose.
- **Thyroid (T3/T4) misuse:** cardiac/bone harm, axis suppression.
- **Insulin misuse:** life-threatening hypoglycaemia.
- **GH misuse:** acromegaly, insulin resistance, tissue overgrowth.



Why clenbuterol is dangerous — a cluster of cardiovascular and systemic harms.

38.1 Clenbuterol

What it is. Clenbuterol is a **β2-adrenergic agonist** — a class of drug that **relaxes airway smooth muscle** (a bronchodilator), used medically for **asthma in some countries** and in **veterinary medicine. It is not an anabolic steroid**, though it's often discussed alongside them because it's misused in the same performance/physique context.

Why it's misused. Clenbuterol stimulates β2 receptors, which **modestly raises metabolic rate and fat oxidation** and exerts **mild anti-catabolic (muscle-sparing) effects** — well demonstrated in livestock (where it's used, controversially, to increase lean meat), less robustly useful in humans. This drives its misuse as a **fat-loss and "cutting" drug.**

The harm profile. Clenbuterol's β2 (and some β1) stimulation causes significant cardiovascular and systemic effects: - **Tachycardia and palpitations**, **cardiac arrhythmias**, - **Cardiac hypertrophy and myocardial injury** with use (structural heart harm), - **Tremor, anxiety, restlessness, insomnia**, headaches, - **Electrolyte disturbances**, notably **hypokalaemia** (low potassium, which itself can cause dangerous arrhythmias), - **Overdose risk** — and critically, clenbuterol[1] has a **long half-life**, so side effects and toxicity **persist for a long time** and are hard to reverse once they occur.

Documented harm. There are reports of **hospitalisations and deaths** from clenbuterol misuse, and from **contaminated meat** (where it's been illegally used in livestock). The combination of **cardiac toxicity and a long half-life** makes it genuinely dangerous — the cardiovascular risk is not theoretical.

◆

PART VII — SYNTHESIS & APPENDICES

Chapter 39 — Putting It Together

▣ Active Summary

The core idea. This final chapter turns the whole book into **one coherent, lifelong plan.** Everything reduces to a **hierarchy of priorities**, a **weekly template**, and a **lifelong arc** — with supplements and pharmacology as fine-tuning on top, never substitutes for the foundation.

The hierarchy (the entire book in one frame): Big Rocks first — don't smoke, build VO_2max, build muscle/strength, keep visceral fat low, sleep 7–9 h, eat whole foods with adequate protein, stay socially connected → **then** diet quality and metabolic markers (BP, glucose, apoB) → **then** evidence-based supplements and clinically-indicated medicine → **then** micro-optimisations. Spend effort in that order.


A complete week: 2–4 resistance sessions (10–20 sets/muscle/week, ~1–2 RIR), **1–2 VO_2max interval sessions**, **2–3 Zone-2 sessions or 8–10k daily steps**, **7–9 h sleep**, **1.6–2.2 g/kg protein**, mostly whole foods.

Periodise life. Alternate **growth/anabolic phases** (training hard, slight surplus, mTOR-driven muscle gain) with **maintenance phases** (energy balance or modest deficit, more autophagy) — never live permanently in either extreme (Chapter 1's longevity tension).

Measure what matters: VO_2max/fitness, strength, body composition (waist-to-height <0.5, FFMI trend), apoB/Lp(a)/BP/glucose, and sleep — re-test and adjust.

◆ Key Points

- **Big Rocks before sand** — secure the high-impact levers first.
- **Train both strength and VO_2max**; keep visceral fat low; sleep; eat whole foods + protein.
- **Periodise growth and maintenance phases** — don't live in either extreme.
- **Measure and track** fitness, strength, body composition, and the key labs.
- **Supplements and drugs are fine-tuning** — the foundation does the work.



Putting it together: the handful of levers that, done consistently, drive the whole outcome.

39.1 The whole book in one hierarchy

Across 36 chapters, one structure recurs: a **hierarchy of impact.** If you remember nothing else, remember the order in which to spend your finite effort:

APPENDICES

Appendix A — Movement Patterns & Exercise Types

Resistance training is best organised around **fundamental movement patterns** rather than individual exercises — covering all patterns trains the whole body in balance (Chapter 7).

Pattern	Primary muscles	Example exercises
Squat (knee-dominant)	Quads, glutes	Back/front squat, leg press, hack squat
Hinge (hip-dominant)	Hamstrings, glutes, back	Deadlift, RDL, hip thrust, good morning
Horizontal push	Chest, front delt, triceps	Bench press, push-up, machine press
Horizontal pull	Mid-back, lats, rear delt	Rows (barbell, dumbbell, cable, machine)
Vertical push	Shoulders, triceps	Overhead press, machine shoulder press
Vertical pull	Lats, biceps	Pull-up, lat pulldown
Carry / core / anti-rotation	Trunk, grip	Farmer's carry, plank, Pallof press
Isolation (accessory)	Single muscle	Curls, extensions, raises, calf work

Compound (multi-joint) exercises give the most stimulus and strength per movement and form the backbone; **isolation** (single-joint) exercises target lagging muscles and allow safe failure. A good program is **compound-led with isolation accessories** (Chapter 7).

Appendix B — Training Splits & Sample Programs

Split	Freq/ muscle	Best for	Trade-offs
Full body	3×/week	Beginners, time-limited, 2–3 days	Hard to fit high volume per session
Upper / Lower	2×/week	Most intermediates (4 days)	Longer sessions
Push / Pull / Legs	1.5–2×/ week	4–6 days, higher volume	Needs ≥5–6 days for 2× frequency
"Bro" split (1 muscle/day)	1×/week	Advanced, high per-session volume	Low frequency — suboptimal vs 2× when volume equated (Chapter 5)

Recommended defaults: Upper/Lower (4 days) or **Full-Body (3 days)** — both deliver the evidence-favoured **~2×/week per-muscle frequency** with manageable session length.

Sample intermediate Upper/Lower week (illustrative): - **Upper A:** bench press, row, overhead press, lat pulldown, triceps extension, biceps curl - **Lower A:** squat, RDL, leg press, seated leg curl, calf raise, core - **Upper**

REFERENCES & FURTHER READING

A curated bibliography of landmark and representative peer-reviewed sources underpinning this book, by section. Cited by author/journal/year for retrieval; this is established literature. For exact DOIs or the latest additions on any topic, a targeted literature search is recommended.

Aging biology & longevity (Part I) - López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. "The Hallmarks of Aging." *Cell* 2013. - López-Otín C, et al. "Hallmarks of aging: An expanding universe." *Cell* 2023. - Mandsager K, et al. "Association of cardiorespiratory fitness with long-term mortality." *JAMA Netw Open* 2018. - Leong DP, et al. "Prognostic value of grip strength (PURE study)." *Lancet* 2015. - Momma H, et al. "Muscle-strengthening activities and mortality: meta-analysis." *Br J Sports Med* 2022. - Li Y, et al. "Healthy lifestyle factors and life expectancy." *Circulation* 2018. - Holt-Lunstad J, et al. "Social relationships and mortality risk: meta-analysis." *PLoS Med* 2010.

Longevity pharmacology (Part I, Ch. 3) - Bannister CA, et al. "Metformin and survival in diabetics vs non-diabetic controls." *Diabetes Obes Metab* 2014. - Konopka AR, et al. "Metformin blunts exercise-induced adaptations." *Aging Cell* 2019. - ITP (NIA Interventions Testing Program) reports on rapamycin, acarbose, 17α-estradiol. - SELECT trial (semaglutide and cardiovascular outcomes), *NEJM* 2023.

Training science (Part II) - Schoenfeld BJ, et al. "Dose-response of weekly resistance training volume and hypertrophy: meta-analysis." *J Sports Sci* 2017. - Schoenfeld BJ, et al. "Resistance training frequency and hypertrophy: meta-analysis." *Sports Med* 2016. - Schoenfeld BJ, et al. "Low- vs high-load resistance training: meta-analysis." *J Strength Cond Res* 2017. - Schoenfeld BJ, et al. "Longer rest periods enhance strength and hypertrophy." *J Strength Cond Res* 2016. - Refalo MC, et al. "Proximity to failure and hypertrophy: systematic review." *Sports Med* 2023. - Maeo S, et al. Lengthened-position training and regional hypertrophy. *Med Sci Sports Exerc / Eur J Sport Sci* 2023. - Roberts LA, et al. "Cold-water immersion attenuates training adaptations." *J Physiol* 2015. - Paulsen G, et al. "Vitamin C and E blunt training adaptations." *J Physiol* 2014. - Israetel M, et al. Renaissance Periodization volume-landmark framework (MV/MEV/MAV/MRV).

Nutrition & body composition (Part III) - Morton RW, et al. "Protein supplementation and resistance-training gains: meta-analysis." *Br J Sports Med* 2018. - Areta JL, et al. "Protein timing/distribution and MPS." *J Physiol* 2013. - Trommelen J, van Loon LJC, et al. "Anabolic response to large protein boluses." *Cell Rep Med* 2023. - Trexler ET, et al. "Metabolic adaptation to weight loss." *J Int Soc Sports Nutr* 2014. - Byrne NM, et al. "Intermittent energy restriction (MATADOR)." *Int J Obes* 2018. - Gardner CD, et al. "Low-fat vs low-carb (DIETFITS)." *JAMA* 2018. - Estruch R, et al. "Mediterranean diet and cardiovascular events (PREDIMED)." *N Engl J Med* 2018. - Kouri EM, et al. "Fat-free mass index in steroid users and nonusers." *Clin J Sport Med* 1995.

Organ-system health (Part IV) - Ference BA, et al. "LDL/apoB causes atherosclerosis: consensus statement." *Eur Heart J* 2017. - Reynolds A, et al. "Carbohydrate quality and health (fibre)." *Lancet* 2019. - Watson SL, et al. "High-intensity resistance and impact training (LIFTMOR)." *J Bone Miner Res* 2018. - Devries MC, et al. "Higher protein and kidney function in healthy adults." *J Nutr* 2018. - Singh B, et al. "Physical activity for depression/anxiety: umbrella review." *Br J Sports Med* 2023. - Schuch FB, et al. "Exercise as treatment for depression: meta-analysis." *J Psychiatr Res* 2016. - Wastyk HC, Gardner CD, Sonnenburg JL, et al. "Fermented-food diet and microbiome." *Cell* 2021. - Hughes MCB, et al. "Sunscreen and skin aging: RCT." *Ann Intern Med* 2013. - Manson JE, et al. "Marine omega-3 and cardiovascular disease (VITAL)." *N Engl J Med* 2019.